picture
RJR-logo

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

icon

Bibliography Options Menu

icon
QUERY RUN:
20 Nov 2026 at 01:37
HITS:
52500
PAGE OPTIONS:
Hide Abstracts   |   Hide Additional Links
NOTE:
Long bibliographies are displayed in blocks of 100 citations at a time. At the end of each block there is an option to load the next block.

Bibliography on: Alzheimer Disease — Current Literature

RJR-3x

Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About:  RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE

RJR: Recommended Bibliography 20 Nov 2026 at 01:37 Created: 

Alzheimer Disease — Current Literature

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.

Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion

Citations The Papers (from PubMed®)

-->

RevDate: 2026-11-18

Ehret F, Fontanesi J, Wilson GD, et al (2026)

Low-dose, high hopes? The potential of radiation therapy in Alzheimer's disease.

RevDate: 2026-11-18

Hussain I, Ali A, Khan S, et al (2026)

Unraveling the Inhibitory Potential of Hydrazone Derivatives Against Cholinesterases: Molecular Interactions, Kinetic Behavior and Structural Features.

Archives of biochemistry and biophysics pii:S0003-9861(26)00336-X [Epub ahead of print].

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with impaired cholinergic neurotransmission. Inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) represents an established approach to its symptomatic management. In this study, five pyridine-based Schiff base derivatives (3a-3e) were synthesized through the condensation of 2-((6-chloropyridin-2-yl)oxy)acetohydrazide with substituted aromatic aldehydes, affording the target compounds in 84-90% yields. Their structures were characterized using spectroscopic techniques, and their in vitro cholinesterase inhibitory activities were evaluated using galantamine as the reference inhibitor. Compound 3b exhibited the greatest inhibitory activity within the series against both AChE and BuChE, with IC50 values of 48.75 and 32.50 μM, respectively, although galantamine showed greater potency (40.30 and 28.88 mM, respectively). Molecular docking was subsequently performed to explore the potential binding orientations and interactions of the synthesized compounds with the selected cholinesterase targets. Overall, the experimental findings identify 3b as the most active derivative within this series, while the docking results provide complementary computational insights. Further experimental validation, including confirmation of inhibitory potency, enzyme kinetics, and cellular toxicity, is required to establish its biological potential. These findings provide a preliminary basis for further investigation of pyridine-based hydrazone derivatives as cholinesterase inhibitors.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Xie W, Wang Y, Li L, et al (2026)

[Research progress on the neuro-endocrine-immune regulatory mechanism of acupuncture in the treatment of Alzheimer's disease].

Zhen ci yan jiu = Acupuncture research, 51(11):1553-1563.

Acupuncture can effectively improve cognitive function and delay disease progression in patients with Alzheimer's disease (AD). Studies have shown that acupuncture treatment for AD is closely related to the effective regulation of the neuro-endocrine-immune (NEI) network. This article reviews the NEI mechanism of acupuncture in the treatment of AD mainly from the following aspects: benign regulation of the nervous system--regulating levels of central neurotransmitters (cholinergic, monoaminergic, amino acid, neuropeptide) and their receptors, brain-derived neurotrophic factor levels, and regulation of neuronal cell cycle re-entry; regulation of the endocrine system--ameliorating hypothalamic-pituitary-adrenal axis dysfunction, regulating levels of related hormones (estrogen, testosterone) and insulin-like growth factor-1; regulation of the immune system--modulating activation of central neuroimmune cells (microglia, astrocytes) and homeostasis of the peripheral immune system, and regulating related inflammatory signaling pathways (such as Toll-like receptor 4/nuclear factor-κB, Janus kinase 2/signal transducer and activator of transcription 3, phosphatidylinositol 3-kinase/protein kinase B, etc.). This article aims to provide a basis for further exploring the mechanism and clinical applications of acupuncture in the treatment of AD.

RevDate: 2026-11-18

Chen P, Tao M, Han S, et al (2026)

Spontaneous Intermolecular Cross-Linking Produces Aβ Dimers With Multiple Alzheimer's Disease Relevant Activities.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Epub ahead of print].

Despite success of therapies targeting the amyloid β-protein (Aβ), the molecular identity of the forms of Aβ which contribute to Alzheimer's disease (AD) remains poorly understood. SDS-stable Aβ dimers are present in higher-order aggregates and exert disease-relevant toxicity, but whether dimers form before or after large aggregates, or how dimers contribute to AD pathogenesis were previously unknown. Here, we report that covalently cross-linked Aβ1-42 dimers can form spontaneously upon prolonged incubation of Aβ fibrils and contain isopeptide bonds (Asp1-Glu22 and Asp1-Asp1), the same as those identified in dimers found in AD brain. Importantly, dimer-enriched Aβ aggregates (DEBA) are structurally distinct to dimer-poor aggregates (DPBA) and have enhanced resistance to proteolysis. Functionally, DEBA exhibit stronger binding to microglia, induce transcription of key pro-inflammatory cytokines, nucleate into plaque-like structures with microglia in vitro, and exacerbate amyloid deposition in App[NL-F/NL-F] mice. DEBA do not appear to be overtly neurotoxic, whereas solubilized DEBA induce toxicities reminiscent of that caused by Aβ-containing AD brain extract. These findings demonstrate prolonged incubation of fibrillar Aβ aggregates results in spontaneous formation of cross-linked dimers, and this is associated with changes in aggregate morphology and emergence of multiple disease-relevant activities.

RevDate: 2026-11-18

Nowrangi MA, Sharma A, Rosenberg PB, et al (2026)

Influence of Apathy on Financial Capacity: A Longitudinal Analysis of the ADNI Cohort.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry pii:S1064-7481(26)00569-5 [Epub ahead of print].

Apathy is the most prevalent neuropsychiatric symptom across the Alzheimer's disease (AD) spectrum, yet its relationship to financial capacity (FC) has not been systematically examined. We analyzed longitudinal data from 1,024 ADNI participants (575 cognitively normal, 353 mild cognitive impairment [MCI], 96 AD dementia) who completed 2,262 Financial Capacity Instrument-Short Form (FCI-SF) assessments, measuring apathy via a three-item GDS subscale (GDS-3) and the NPI-Q. Hierarchical linear mixed-effects models examined cross-sectional, lagged, trajectory, and cognitively-adjusted apathy-FC associations. Greater apathy predicted lower FCI-SF scores (GDS-3: β = -1.26; NPI-Q: β = -4.49, both p <0.001) and slower completion times (GDS-3: β = 10.89 sec; NPI-Q: β = 23.22 sec, both p <0.001), with effects most consistent in MCI. Informant-rated apathy at prior visits predicted subsequent decline in FCI-SF scores (β = -4.30) and completion time (β = 38.03 sec; both p <0.001). Baseline apathy and depression were associated with attenuated increases in completion time over follow-up, likely reflecting range restriction from elevated baseline values. Apathy associations persisted after controlling for executive, memory, and visuospatial performance, with depression showing similar but generally weaker effects. Apathy is a consistent, partially independent predictor of FC impairment across the AD spectrum, most pronounced in MCI and robust to cognitive adjustment. Both accuracy- and efficiency-based FC endpoints were affected, supporting completion time as a clinically meaningful outcome. Systematic assessment and treatment of apathy may help preserve financial independence in at-risk or affected older adults.

RevDate: 2026-11-18

Maqsood L, Azeem F, Zubair M, et al (2026)

Differential Expression and Therapeutic Targeting of K[+] Channels in Neurological Disorders: An Integrative Approach.

Omics : a journal of integrative biology [Epub ahead of print].

Potassium (K[+]) channels regulate cellular homeostasis and electrical signaling, particularly in the nervous system, and their dysfunction is linked to neurological disorders such as epilepsy, Alzheimer's disease (AD), and Parkinson's disease (PD). In this study, Gene Expression Omnibus (GEO) datasets (GSE252132, GSE190451, and GSE160299) were analyzed using GEO2R to identify differentially expressed K[+] channel genes. A total of 2741, 3681, and 861 differentially expressed genes were identified in AD, epilepsy, and PD, respectively, including the common K[+] channel genes KCNJ5, KCNJ6, and KCNJ12. Functional enrichment using Enrichr highlighted potassium ion transport, potassium channel complexes, voltage-gated potassium channel activity, and gonadotropin-releasing hormone secretion. STRING and Cytoscape-based protein-protein interaction and Molecular Complex Detection analyses identified 13 hub genes, including KCNJ6, KCNJ5, and KCNJ12. miRNet analysis identified 12 miRNAs, 1 transcription factor, and 7 target genes, with hsa-miR-138-5p predicted to regulate KCNJ6. Virtual screening of 2315 Food and Drug Administration-approved drugs and 2390 Traditional Chinese Medicine compounds identified Sorafenib, Hinokiflavone, Posaconazole, and 1,3,6-Tri-O-galloyl-beta-D-glucose as promising KCNJ6-binding candidates. These findings highlight K[+] channels, particularly KCNJ6, as biomarkers and therapeutic targets in neurological disorders.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Hoagey DA, McKay NS, Joseph-Mathurin N, et al (2026)

Exploring healthy aging through preclinical Alzheimer disease in the Knight Alzheimer Research Imaging dataset.

Nature communications, 17(1):.

Alzheimer disease (AD) remains a significant global public health challenge, requiring robust multimodal datasets to elucidate its prolonged preclinical phase, improve early detection, advance understanding of disease trajectories, and guide intervention strategies. Here we present the Knight Alzheimer Research Imaging (KARI) dataset, established by the Washington University Knight ADRC to address this critical need. We detail comprehensive multimodal neuroimaging from 1,645 participants (aged 42-97) across 6,217 acquisitions. Spanning the AD spectrum from healthy aging to symptomatic disease, the cohort undergoes extensive longitudinal imaging using structural and functional magnetic resonance imaging (MRI) alongside positron emission tomography (PET) tracers for amyloid and tau pathology. This is complemented by rich clinical, cognitive, genetic, and biomarker data. In addition to raw imaging, the dataset provides quality-controlled processed outputs, including anatomical segmentations and biomarker quantification. By making this data accessible to researchers, the Knight ADRC aims to accelerate discoveries in pathophysiology, biomarker identification, and therapeutic development.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Yim S, Lee EH, Lee J, et al (2026)

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer's disease.

Nature communications, 17(1):.

Plasma biomarkers that reflect distinct stages of Alzheimer's disease (AD) could enable scalable biological staging. We evaluated phosphorylated tau (p-tau) species across multiple analytical platforms and the endogenously cleaved microtubule-binding region containing residue 243 (eMTBR-tau243) using a dedicated LC-MS/MS platform in a well-characterized cohort with amyloid PET and a subset with tau PET. While T1 biomarkers increased during preclinical stages, eMTBR-tau243 and p-tau205 increased later, consistent with fibrillar tau aggregation. eMTBR-tau243 showed the strongest and stage-dependent associations with regional tau PET and cognition, outperforming T1 biomarkers in predicting cross-sectional and longitudinal cognition. A plasma-based tau staging system integrating p-tau217 and eMTBR-tau243 closely aligned with PET-based tau staging and predicted longitudinal cognitive trajectories. These findings support plasma eMTBR-tau243 as a prototypical T2 biomarker and highlight the potential of plasma-based tau staging for prognosis and therapeutic decision-making in AD.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Song C, Yao W, Hu X, et al (2026)

Stenotrophomonas maltophilia alleviates Alzheimer's disease model phenotype by inhibiting Aβ aggregation via autophagy.

NPJ biofilms and microbiomes, 12(1):.

Probiotics exert neuroprotective effects against Alzheimer's disease (AD) through modulation of gut-brain axis signaling pathways, yet disease-modifying therapies remain elusive. In this study, we demonstrate that Stenotrophomonas maltophilia (S. maltophilia) ameliorates AD-associated pathological and behavioral phenotypes in Caenorhabditis elegans (C. elegans) models, including learning deficits and paralysis. Mechanistically, S. maltophilia suppresses β-amyloid (Aβ) peptide aggregation by orchestrating the activation of conserved cellular pathways: autophagy, innate immune signaling, and unfolded protein responses in the mitochondria (UPRmt) and endoplasmic reticulum (UPRer). Specifically, S. maltophilia induces UPRmt in an atfs-1-dependent manner and activates UPRer via the PERK kinase PEK-1. Further mechanistic analysis suggests that S. maltophilia initiates a signaling cascade: activation of ATF-7 immune pathways enhanced autophagy and subsequent clearance of Aβ aggregates. Metabolomic screening further pinpointed pizotifen as a bioactive metabolite that might inhibit Aβ aggregation through immune modulation.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Liu X, Luo L, Pritschet L, et al (2026)

Early menopause is associated with reduced global brain activity.

npj aging, 12(1):.

Menopause affects the aging process in women through a significant decline in ovarian hormone production in midlife. Women who experience early menopause show accelerated physiological aging, poorer memory, and increased risk of neurodegenerative diseases. However, how menopause timing affects brain activity remains unclear, which could be crucial for understanding early menopause-related aging acceleration and increased risk of dementia. Recent studies have revealed a highly structured infra-slow (<0.1 Hz) global brain activity and linked it to arousal and memory functions, as well as waste clearance in Alzheimer's disease (AD). Here, we examined how this global brain activity relates to age at menopause using resting-state fMRI data from the Human Connectome Project-Aging dataset. We found that women with earlier menopause (mean menopausal age 45 ± 3.5 yr) exhibited weaker global brain activity with reduced coupling to cerebrospinal fluid (CSF) flow compared to age-matched later-menopausal women (mean menopausal age 54 ± 1.2 yr). Differences appeared mainly in higher-order brain regions, where activation levels correlated with memory performance in earlier but not in intermediate or later menopausal women. These findings highlight brain activity changes linked to early menopause, suggesting a potential mechanism underlying memory decline and the increased risk of AD and dementias in early-onset menopausal women.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Llorente-Saguer I, Arber C, NP Oxtoby (2026)

Theta: a multivariate normative statistic applied to amyloid β panel data in familial Alzheimer's disease.

NPJ systems biology and applications, 12(1):.

Biomarker ratios often outperform individual biomarkers in complex, multifactorial diseases. In Alzheimer's disease, bivariate ratios may fail to capture the complex stoichiometry of amyloid β (Aβ) processing. We extended the ratio concept into a multivariate framework and performed experiments on Aβ peptide data from four familial Alzheimer's disease cohorts (8 controls, 223 PSEN1 mutation carriers). We define "theta" as a multivariate statistic quantifying the angular divergence of each subject's peptide profile from a homeostatic norm. Performance was benchmarked against established Aβ ratios using AUC and precision-recall AUC. Theta consistently outperformed benchmarks across datasets, achieving near-perfect discrimination (AUC 0.999, PR AUC 0.964). Established ratios like Aβ42/40 and Aβ37/42 showed markedly lower precision-recall performance (0.201-0.410). Pairwise comparisons confirmed theta's superiority. Theta leverages the full multi-peptide Aβ profile, treating it as a unified geometric entity in the spirit of systems-level thinking, addressing the inherent limitations of simple pairwise ratios. Its consistent performance across diverse PSEN1 mutations underscores its robustness and suggests utility for early and precise detection of pathogenic shifts. Additional validation in human biospecimens is needed, and the framework may extend to sporadic Alzheimer's disease and broader multivariate modelling challenges such as differential diagnosis.

RevDate: 2026-11-18

Warmenhoven N, Binette AP, Collij LE, et al (2026)

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology.

Nature aging [Epub ahead of print].

Plasma biomarkers for Alzheimer's disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ42/Aβ40 and p-tau181/Aβ42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic (n = 129), a primary care (n = 220) and a research cohort (n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83-91%) and p-tau217/Aβ42 (83-92%) had comparable accuracies to CSF (88-90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90-97%) remained comparable to CSF (91%) in the clinical cohorts (all Padj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Dan T, Huang X, Ding J, et al (2026)

Understanding mechanistic role of structural and functional connectivity in tau propagation through multilayer modeling.

NPJ digital medicine, 9(1):.

Emerging neuroimaging evidence shows that pathological tau proteins build up along specific brain networks, suggesting that large-scale network architecture plays a key role in the progression of Alzheimer's disease (AD). However, how the interaction between structural (SC) and functional connectivity (FC) is associated with tau propagation remains largely unexplored. Using longitudinal neuroimaging data, we develop a multi-layer graph diffusion model to investigate this interplay. We identify a regionally asymmetric pattern, FC dominates tau accumulation in subcortical, insular, and frontotemporal regions, whereas SC prevails in occipital, parietal, and limbic areas. The principal conduit of tau propagation shifts from FC-mediated spread in early stages to SC-constrained diffusion as the disease advances. Furthermore, these propagation patterns correlate with regional expression of AD-associated genes (e.g., CHUK, TMEM106B, MCL1, NOTCH1, TH) and are selectively modulated by risk factors like APOE genotype and biological sex. By disentangling these dynamic pathways, our framework enables personalized trajectory prediction and refined patient stratification. These findings offer mechanistic insights into selective regional vulnerability, providing a quantitative basis for stage-specific therapeutic targeting and the optimization of clinical trial designs through network-based biomarkers. Our results are validated in an independent cohort, yielding consistent findings.

RevDate: 2026-11-18

Yu D, Germann J, Murtaza G, et al (2026)

Hypothalamic volume and cell-type changes in ageing and Alzheimer's disease.

Nature [Epub ahead of print].

Alterations in metabolism, stress response, sleep, circadian rhythms and neuroendocrine processes are key features of ageing and neurodegeneration[1,2]. These fundamental processes are regulated by the hypothalamus, yet how its functionally distinct subregions and cell types change during human ageing and Alzheimer's disease (AD) remains largely unexplored. Here we present HypoAD, an atlas of the human hypothalamus in ageing and AD, including high-resolution magnetic resonance imaging from 458 individuals and single-nucleus RNA sequencing of 614,403 nuclei from young participants, patients with AD and age-matched non-dementia control participants. We show that hypothalamic subregions governing metabolism, stress and circadian rhythms are particularly vulnerable, showing notable changes in both volumes and gene expression during ageing and AD. At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD. These signatures were reflected in specific cell types: microglia transitioned to a pro-inflammatory state, whereas inhibitory neurons within sleep-regulating and circadian-regulating hypothalamic subregions showed the most profound transcriptional alterations, including disruptions in ligand-receptor interactions and G-protein-coupled receptor signalling. HypoAD provides a high-resolution volumetric map and a transcriptomic atlas of the human hypothalamus in ageing and AD, relating lifestyle and behavioural changes to the relevant volumetric and molecular pathways. In addition, HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression.

RevDate: 2026-11-18

Yoon SW, Nam YJ, Hong SH, et al (2026)

Impaired cellular stress adaptability in Alzheimer's disease patient-derived fibroblasts: a PFKFB3-linked transcriptomic response to oxidative stress.

GeroScience [Epub ahead of print].

Aging-related impairment in cellular stress adaptability may contribute to vulnerability to Alzheimer's disease (AD), but patient-derived experimental models that preserve agingassociated molecular features remain underused. Here, we investigated transcriptomic responses to oxidative stress in ex vivo dermal fibroblasts derived from patients with AD and control participants matched for age and sex. Fibroblasts were exposed to hydrogen peroxide to induce reactive oxygen species-mediated stress, followed by RNA sequencing to identify disease-associated differences in stress-responsive gene regulation. AD-derived fibroblasts exhibited distinct oxidative stress response patterns, with altered regulation of pathways related to endoplasmic reticulum stress, immune activation, autophagy, protein synthesis, and cell cycle control. Systematic candidate gene prioritization identified PFKFB3 as a key stress-responsive gene showing reduced induction in AD fibroblasts. Lower PFKFB3 responsiveness was associated with poorer cognitive performance and higher levels of neurodegeneration-related blood biomarkers, including plasma pTau217, neurofilament light chain, and glial fibrillary acidic protein. In immortalized human astrocytes, PFKFB3 knockdown reduced cell viability under oxidative stress and altered transcriptional programs related to proteostasis, metabolic regulation, and immune activation. These findings suggest that AD is associated with impaired cellular stress adaptability in patient-derived fibroblasts and highlight PFKFB3 as a candidate node linking oxidative stress responsiveness, glial vulnerability, and AD-related pathological burden.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Li S, Tan J, Zi D, et al (2026)

Alzheimer's disease and cancer as opposing failures of APP signaling network homeostasis: from pleiotropic components to multi-target therapeutics.

Molecular medicine (Cambridge, Mass.), 32(1):.

The inverse epidemiological relationship between Alzheimer's disease (AD) and cancer has been previously explained by a "Cleavage Pathway Imbalance" in amyloid precursor protein (APP) proteolysis. Here we expand this model into a dynamic, multi-dimensional APP signaling network that integrates extracellular cues, intracellular adaptors, organelle-contact dynamics, and proteolytic events. In AD, the network undergoes catastrophic post-mitotic collapse, driven by endolysosomal dysfunction, impaired autophagy, and downstream mitochondrial failure, resulting in synaptic degeneration. In cancer, the same network is hijacked to sustain proliferative, invasive, and immunoevasive programs. Crucially, network components such as BACE1 and ADAM10 act as neurodegenerative drivers in the brain yet as oncogenic promoters in peripheral tissues. We advocate a shift from reductionist single-pathway inhibition to rational, multi-target strategies that restore system-wide network homeostasis. Embracing this context-aware, network-based framework is essential for developing safer and more effective therapeutics for these two major age-related disorders.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Zhang Y, Chen M, Xiang J, et al (2026)

Dual-view global and mechanism-aware propagation for disease-gene association prediction.

BMC bioinformatics, 27(1):.

BACKGROUND: Understanding the associations between diseases and genes is essential for uncovering disease mechanisms and guiding therapeutic development. Given the high cost and time-consuming nature of experimental validation, computational prediction methods have become an effective approach for exploring potential disease-gene associations.

RESULTS: Capturing both global network structure and latent mechanistic signals remains challenging in heterogeneous disease-gene networks. This paper proposes DGMAP, a dual-view global and mechanism-aware propagation framework for disease-gene association prediction. DGMAP first constructs a neighborhood view based on inter-node similarity. It then introduces a cross-view collaborative propagation mechanism to capture global structural information. A mechanism-aware disentanglement strategy is further designed to uncover latent interaction patterns. In addition, intra- and inter-view contrastive learning objectives are incorporated to improve node representations by aligning structural and mechanistic embeddings.

CONCLUSIONS: Extensive experiments show that DGMAP achieves consistently better overall performance than existing methods in disease-gene association prediction. The Alzheimer's disease case study further demonstrates its practical value: DGMAP identifies biologically relevant candidate genes, with 15 of the top 20 predictions supported by literature. Mechanism visualization and network bias analysis also show that these predictions reflect coherent and diverse disease-related mechanisms.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Alsharayri S, Kianfar N, Knox S, et al (2026)

Application of Medicare Part D data in Alzheimer's disease and related dementias: a scoping review.

BMC geriatrics, 26(1):.

BACKGROUND: Although Medicare Part D data are extensively used in pharmacoepidemiologic research, no previous synthesis has assessed their role in studies of Alzheimer's disease and related dementias (ADRD). This scoping review aims to map how Medicare Part D data have been employed to examine medication use, adherence, disparities, and outcomes among individuals with ADRD.

METHODS: We systematically searched PubMed/MEDLINE, CINAHL, Scopus, and Web of Science for peer-reviewed studies published between January 1, 2006, and March 31, 2025, with no age restrictions applied. Eligible studies evaluated medication use (antidementia therapies, antipsychotics, or symptomatic management) in ADRD populations using Medicare Part D data.

RESULTS: Fifty-three studies met the inclusion criteria. Most were nationwide in scope (86.8%) and employed cohort design (56.6%). Antipsychotics were the most examined medication class (60.4%), followed by dementia-specific therapies (52.8%) and symptomatic management agents (34.0%). The most frequently assessed outcomes involved patterns of medication use (71.7%), followed by clinical and safety outcomes (28.3%), disparities (20.8%), adherence and persistence (9.4%), and healthcare costs or utilization (5.7%). Just over half of the studies (50.9%) utilized Part D Prescription Drug Event files, whereas a small fraction incorporated formulary data (1.9%) or Medicare Current Beneficiary Survey linkages (9.4%). Regression models were used in 60.4% of studies, while survival analysis (20.8%), causal inference (13.2%), and policy evaluation (11.3%) were applied less frequently.

CONCLUSIONS: This review lays the groundwork for Medicare Part D research in ADRD, highlighting the need to expand studies on adherence, treatment effectiveness, policy, equity, and advanced analytic approaches.

RevDate: 2026-11-18
CmpDate: 2026-11-19

Jiao F, Li Y, Zhang L, et al (2026)

Therapeutic regimen for AD-derived MCI: the effect of sodium oligomannate (GV-971) combined with donepezil on patients' cognitive function and hippocampal atrophy rate.

BMC neurology, 26(1):.

PURPOSE: To investigate the clinical efficacy of sodium oligomannate (GV-971) combined with donepezil in the treatment of patients with mild cognitive impairment (MCI) in Alzheimer's disease (AD).

METHODS: This non-randomized, open-label, retrospective analytic study included 100 patients with AD-derived MCI who were treated in our hospital between May 2023 and May 2024, and were divided into two groups according to the different treatment modalities recorded in the electronic medical record system: 44 cases in the control group (donepezil), and 56 cases in the observation group (sodium oligomannate (GV-971) combined with donepezil). Cognitive function, biochemical markers (homocysteine (Hcy), S100 calcium binding protein B (S100β), neuron-specific enolase (NSE)), serum intestinal flora metabolic markers (phenylalanine (Phe), short-chain fatty acids (SCFA), γ-aminobutyric acid (GABA), acetylcholine (Ach)), hippocampal volume, and adverse effects were collected and compared between the two groups, and adverse reactions were recorded.

RESULTS: After treatment, the comparison of various scores of cognitive function, Hcy, S100β, NSE, Phe, SCFA, GABA, and Ach between the patients in the observation group and the control group showed statistically significant differences (P<0.05); after treatment, the comparison of left hippocampal volume, right hippocampal volume, and total volume between the observation group and the control group did not show any statistically significant difference (P>0.05). In contrast, the calculated hippocampal atrophy rate-derived from the percentage change relative to baseline volume-was significantly lower in the observation group than in the control group (P < 0.05). Regarding safety, the total incidence of adverse reactions was 10.71% (6/56) in the observation group versus 9.09% (4/44) in the control group, with no statistically significant difference between the two groups (P > 0.05).

CONCLUSION: The combination of sodium oligomannate (GV-971) and donepezil was associated with more favorable changes in cognitive function, neuronal injury biomarkers, serum markers of gut microbiota metabolism, and a slower observed rate of hippocampal atrophy in patients with AD-derived MCI. These associations do not imply causation, and the combination regimen did not significantly increase adverse reactions in this cohort.

RevDate: 2026-11-18
CmpDate: 2026-11-19

Li Y, Fu F, Cao J, et al (2026)

The diagnostic and therapeutic potential of palmitoylation-related genes in Alzheimer's disease.

BMC neurology, 26(1):.

BACKGROUND: Alzheimer's disease (AD) is a highly heterogeneous disorder, for which early accurate diagnosis and subtype stratification remain clinically challenging. Palmitoylation, a critical reversible post‑translational modification, has been implicated in the pathological progression of AD. However, a comprehensive investigation of palmitoylation‑related pathway genes in the context of AD diagnosis and molecular subtyping is still lacking.

METHODS: Transcriptomic data from three AD cohorts in the GEO database were integrated and corrected for batch effects. Palmitoylation‑related differentially expressed genes (PR‑DEGs) were screened through differential expression analysis combined with weighted gene co‑expression network analysis (WGCNA). Based on these PR‑DEGs, molecular subtyping, pathway enrichment, and immune infiltration analyses were performed in AD. Twelve machine learning algorithms were employed to construct 113 classification models, and core palmitoylation‑related biomarkers with stable cross‑cohort performance were identified via multi‑algorithm cross‑screening. Model generalizability was validated using two independent external GEO datasets (GSE132903 and GSE138260). In addition, SHAP analysis, single‑cell transcriptomics, regulatory network construction, and drug prediction were integrated to elucidate the biological functions and clinical potential of the core genes.

RESULTS: In this study, 15 core PR‑DEGs were identified, and AD was stratified into two heterogeneous subtypes: subtype C1, whose palmitoylation profile resembled that of normal aging, and subtype C2, which exhibited pronounced palmitoylation suppression, synaptic impairment, and immune dysregulation. A random forest model constructed based on the PR‑DEGs demonstrated stable and excellent diagnostic performance, with consistently high area under the curve (AUC) values across multiple cohorts. Six core diagnostic genes were further screened, among which CHRM1 showed the highest diagnostic value and model contribution, along with a neuron‑specific aberrant expression pattern. These core genes exhibited coordinated dysregulation and were implicated in multiple AD‑relevant pathways, including synaptic homeostasis, lipid metabolism, Wnt signaling, and neuroinflammation. In addition, several potential targeted therapeutic agents were predicted.

CONCLUSION: In this study, a preliminary machine learning‑based diagnostic and subtype stratification analytic framework for AD was constructed based on the palmitoylation pathway. Bioinformatics analyses suggested that core genes, including CHRM1, PORCN, CRMP1, GNG3, CLIP3and ACOT7, may hold promise as potential biomarkers for precise diagnosis and targeted intervention in AD, thereby providing a theoretical reference for early screening, personalized mechanistic investigation, and therapeutic exploration.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Li L, Gu S, He C, et al (2026)

13-Methylpalmatine liposome targeted binding to Armcx4 to restore mitochondrial function and improve vascular dementia.

Journal of nanobiotechnology, 24(1):.

BACKGROUND: Vascular dementia (VD) is the second most common type of dementia after Alzheimer's disease, accounting for 15%-20% of all dementia cases. Its incidence continues to rise with the aging of the population. In 2021, there were approximately 56.9 million dementia patients worldwide, and this number is projected to exceed 137 million by 2050, imposing a heavy burden on patients' families and the medical system. Currently, there are no specific drugs available for the treatment of this disease in clinical practice.

RESULTS: From the TCMSP database, the dominant monomer palmatine (Pal) was selected from 48 individual molecules. However, its low bioavailability limited its application. By introducing a methyl group at the C-13 position based on the magic methyl effect, the resulting monomer 13-methylpalmatine (13MP) significantly outperformed Pal in terms of drug activity and molecular docking. We established 13MP as the core active compound. Subsequently, we fabricated an angiopep-2-modified brain-targeted liposomal delivery system (13MP-LIP-A) via thin‑film hydration. The system exhibited uniform particle size and favorable stability. The results showed that angiopep-2 modification significantly enhanced cellular uptake in HT22 cells and improved brain‑targeted distribution in vivo, effectively overcoming the bioavailability limitations of 13MP. The formulation alleviated oxidative stress, preserved mitochondrial function, and upregulated the expression of neurotrophic factors in vitro. In a VD mouse model, 13MP-LIP-A ameliorated cognitive deficits, restored cerebral blood flow, and attenuated neuronal pathology. Mechanistically, cross‑species transcriptomic analysis identified Armcx4 as a key mitochondrial‑associated target, and 13MP-LIP-A reversed its pathological downregulation. Knockdown of Armcx4 abrogated the protective effects on mitochondrial dynamics and function, suggesting that Armcx4 is an important mediator of the therapeutic response.

CONCLUSIONS: In conclusion, this study successfully developed a liposome-based formulation that represents a promising preclinical candidate for VD intervention. The formulation exerts neuroprotective effects, with Armcx4 identified as a key contributor to the observed mitochondrial regulation, providing a new experimental basis for further mechanistic and translational investigation.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Moezzi D, Gorter R, Rayatpour A, et al (2026)

Iron dysregulation: implications for pathology in multiple sclerosis.

Molecular neurodegeneration, 21(1):.

In neurological diseases including Alzheimer's disease, Parkinson's disease and multiple sclerosis, iron overload is a major contributor to oxidative stress and localized injury. Iron can also cause harm through oxidative stress-independent mechanisms such as protein aggregation and abnormal sphingolipid metabolism. Dysregulation of iron homeostasis may occur systemically or within specific tissues, leading to deficiency, overload or intracellular mislocalization. These alterations disrupt cellular functions and contribute to disease pathology. Iron's ability to accept and donate electrons is essential for oxygen transport, energy production and DNA synthesis, yet this same reactivity also renders it potentially toxic, as excess iron promotes cellular damage including ferroptosis. Despite extensive research into the functions of iron under physiological conditions and its toxicity when dysregulated, critical questions remain unanswered. Why is iron homeostasis disrupted in the brain? What are the underlying mechanisms driving this dysregulation, and how can the resulting damage be mitigated or reversed? These questions are especially pertinent in the context of demyelinating and neurodegenerative disorders, where iron accumulation is a common pathological feature. In this review, we provide a comprehensive overview of iron biology, emphasizing its chemical properties, cellular functions, and the tightly regulated mechanisms that maintain iron homeostasis. We then discuss the pathological consequences of iron dysregulation in multiple sclerosis and the therapeutic strategies that have been developed to target iron toxicity. While the disease of prominence for this review is multiple sclerosis, we refer to countering iron in Alzheimer's and Parkinson's disease to highlight the approaches undertaken to ameliorate iron neurotoxicity.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Sun G, Chen J, Yang H, et al (2026)

Associations of CLivD score with dementia, cardiovascular disease, cancer, and mortality in the general population from the UK biobank.

BMC medicine, 24(1):.

BACKGROUND: The Chronic Liver Disease (CLivD) score is a non-invasive marker of advanced liver disease risk. We evaluated its associations with dementia, cardiovascular disease (CVD), cancer, and all-cause mortality.

METHODS: This prospective cohort study included UK Biobank participants with calculable CLivD scores at baseline (2006-2010). Two previously validated versions of the score were calculated: a laboratory-based CLivD (CLivDlab), incorporating age, sex, waist-hip ratio, alcohol consumption, diabetes, smoking, and gamma-glutamyltransferase (GGT), and a non-laboratory CLivD (CLivDnonlab), based on the same predictors without GGT. Data were analyzed using Cox proportional hazards models, Kaplan-Meier survival curves, and restricted cubic spline functions. Additional models adjusted for centered age and sex.

RESULTS: This prospective cohort study included 88,449 UK Biobank participants with calculable CLivD scores (2006-2010) and a mean 9.76-year follow-up. During follow-up, 1,052 (1.19%) developed dementia, 8,814 (9.97%) experienced CVD, 15,882 (17.96%) were diagnosed with cancer, and 4,944 (5.59%) participants died. Compared to the lowest CLivD quartile (Q1), the highest quartile (Q4) was associated with significantly elevated risks of dementia (CLivDlab: HR = 5.57, 95% CI [4.37-7.11]; CLivDnonlab: HR = 4.39, 95% CI [3.51-5.50]), CVD (CLivDlab: HR = 4.23, 95% CI [3.93-4.55]; CLivDnonlab: HR = 3.59, 95% CI [3.34-3.85]), cancer (CLivDlab: HR = 2.27, 95% CI [2.17-2.38]; CLivDnonlab: HR = 2.11, 95% CI [2.01-2.21]), and mortality (CLivDlab: HR = 4.77, 95% CI [4.31-5.28]; CLivDnonlab: HR = 4.14, 95% CI [3.76-4.56]), all p values < 0.001. Associations were attenuated after additional adjustment for centered age and sex, but the highest CLivDlab quartile remained associated with all four outcomes. Higher CLivD scores were also associated with Alzheimer's disease, vascular dementia, stroke, coronary heart disease, and heart failure. Kaplan-Meier curves showed higher cumulative incidence across increasing CLivD quartiles, and most dose-response associations were nonlinear.

CONCLUSIONS: Higher CLivD scores identified individuals at increased risk of dementia, cardiovascular disease, cancer, and all-cause mortality in the general population. These findings support CLivD as a broad risk stratification marker, while its interpretation should account for demographic components embedded in the score and requires validation in more diverse populations.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Pelkmans W, Cacciaglia R, Kassinopoulos M, et al (2026)

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

Molecular neurodegeneration, 21(1):.

BACKGROUND: Structural brain changes during the earliest asymptomatic stages of Alzheimer's disease (AD) remain poorly understood. Previous research in preclinical AD shows heterogeneous findings, reporting both subtle neuronal loss and paradoxical increases in grey matter (GM) volume. This study applies an extensive cerebrospinal fluid (CSF) biomarker panel to better understand the biological processes underlying longitudinal GM changes in cognitively unimpaired (CU) adults, spanning the amyloid/tau (AT) continuum.

METHODS: We analysed data from 627 CU individuals from three longitudinal cohorts (ALFA+, Wisconsin ADRC, WRAP), with repeated MRI (3.5 ± 0.9 years) and baseline CSF biomarkers from the NeuroToolKit panel (Roche Diagnostics). Using non-negative matrix factorization, we decomposed the CSF biomarker levels into six latent components, reflecting amyloid-β (Aβ) pathology, tau-related pathophysiology with synaptic injury, neuroaxonal injury, microglial reactivity, astrocytic reactivity, and cytokine signalling. We tested associations between component weights and voxel-wise longitudinal GM volume changes using single-component and a joint-all components model. Analyses were performed across the full sample and stratified by AT status. Associations with longitudinal cognitive performance (PACC) were assessed using linear mixed-effects models.

RESULTS: The Aβ pathology component was the strongest and most widespread predictor of longitudinal GM atrophy, predominantly in temporal and frontal regions, also when controlling for tau pathophysiology, neuroaxonal injury, or neuroinflammatory components. Higher Aβ pathology scores were also associated with cognitive decline. The component capturing tau-related pathophysiology and synaptic injury initially associated with GM loss but lost significance after accounting for other biomarker components. In contrast, components reflecting microglial reactivity, astrocytic reactivity, and cytokine signalling were associated with longitudinal GM volume increases, with effects varying by AT stage.

CONCLUSIONS: In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury. While glial and inflammatory processes may contribute to transient GM increases in preclinical AD. A better understanding of these dynamic relationships between structural brain changes and various biological pathways at the earliest stages of AD is crucial to inform the development of interventions before irreversible neurodegeneration occurs.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Salas Nuñez LF, Barrera-Ocampo A, Caicedo PA, et al (2026)

Research EnzyPred: a general model for predicting enzyme-substrate interactions using deep learning, parallel LoRA, and, natural language processing-inspired approaches.

Journal of cheminformatics, 18(1):.

Enzyme-substrate interaction (ESI) prediction is a critical challenge in biocatalysis, with applications in metabolic engineering and drug design. This prediction is valuable because it allows avoiding experimental characterization, a process that can be complex and expensive. In this work, we present EnzyPred, an ESI prediction tool based on Natural Language Processing (NLP), Deep Learning (DL), fine-tuning, Low Range Parallel Adapter (LoRA-P), and Inference-time Prioritized Fine-tuning (PFT) techniques, using representations generated through Evolutionary Scale Modeling (ESM) for enzymes and Extended Connectivity Fingerprinting (ECFP) for substrates. This approach allows training the model with evolutionary, structural, and chemical features, improving performance in identifying interactions. The model was trained on a dataset of 32,833 positive enzyme-substrate pairs, complemented by 32,833 negative pairs generated using soft clustering, molecular descriptors, and Tanimoto similarity. EnzyPred achieved an average accuracy of 86.97%, proving to be competitive with previously presented tools, standing out for its generalization capacity, computational efficiency, and adaptability. Two case studies were used to validate the tool experimentally. In the first, the enzyme that catalyzes the conversion of 4'-O-methylnorbelladine to N-desmethylnarwedine in Amaryllidaceae was sought. For this, the substrate was fixed and tested with predicted enzymes from different transcriptomes reported in the literature for this family. The predicted ones were tested in the laboratory, identifying the enzyme, which contributed to the knowledge of the synthesis pathway of galantamine, a drug used in the treatment of Alzheimer's. In the second case, we searched for compounds that may interact with the enzyme acetylcholinesterase (AChE), for which the enzyme was fixed and we used the ZINC22 database as a search space. 747 compounds with activity were predicted, of which nine were prioritized through clustering for experimental testing, and all presented activity. These results confirm the relevance of this approach to predict molecular interactions, opening new possibilities for the design of enzymatic and synthetic pathways.Scientific contributionThis study introduces EnzyPred, an adaptive deep learning framework for enzyme-substrate interaction prediction that jointly integrates protein language model, molecular fingerprints, and a novel activity-free negative sampling strategy to address data imbalance and false negatives. Unlike previous ESI models, EnzyPred incorporates low-rank adaptation and Inference-time Prioritized Fine-tuning, enabling rapid and targeted model specialization for specific enzyme-substrate pairs without retraining from scratch. The framework is validated across enzyme identification and virtual screening tasks, with experimental confirmation, demonstrating its potential to accelerate biocatalysis discovery and pathway elucidation beyond existing methods.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Liu J, Liu C, Liu J, et al (2026)

Neuron-enriched STAT4 shapes time- and context-dependent neuronal outcomes in Alzheimer's disease.

Translational neurodegeneration, 15(1):.

BACKGROUND: Neuronal dysfunction in Alzheimer's disease (AD) is increasingly linked to dynamic and context-dependent alterations in intracellular signaling. However, how these changes drive progressive neurodegeneration and divergent neuronal outcomes remains poorly understood.

METHODS: Integrative analyses across independent human single-nucleus RNA sequencing datasets were performed to identify neuronal factors consistently altered in AD. Signal transducer and activator of transcription 4 (STAT4) distribution in different cell types was further validated using a mouse single-cell RNA sequencing dataset and experimental models. Functions of STAT4 were examined in human SH-SY5Y cells, mouse HT22 neuronal cells, mouse primary neurons, and inducible systems. In vivo effects were assessed in 3×Tg-AD and wild-type mice with AAV-mediated Stat4 modulation and pharmacological ERK inhibition. Multi-omics approaches, including RNA-seq, Cut&Tag, and RIP-seq, were used to explore downstream regulatory mechanisms.

RESULTS: Integrative analyses identified STAT4 as a neuron-enriched factor consistently reduced in AD neurons. STAT4 supported neuronal integrity and synaptic homeostasis under basal conditions. Inducible restoration of STAT4 expression exerted divergent effects in a time-dependent manner, with early adaptive responses transitioning to later oxidative stress- and apoptosis-associated changes. Sustained STAT4 restoration induced oxidative stress, apoptosis-related signaling, and tau protein-related alterations, which were attenuated by ERK inhibition. In contrast, the beneficial outputs, including reduced Aβ burden and improved synaptic and neuronal markers, were preserved despite ERK inhibition. Parallel analyses in wild-type mice showed a delayed trajectory, indicating disease-context-dependent modulation. STAT4 was further associated with coordinated signaling networks and hnRNPK-related regulatory complexes.

CONCLUSIONS: These findings define a time- and context-dependent signaling framework in which STAT4-associated outputs progressively shift toward maladaptive, ERK-sensitive responses in AD. Selective constraint of the late-stage signaling imbalance may attenuate the pathological outcomes while preserving the beneficial effects, providing a potential strategy for context-specific therapeutic intervention.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Chvátal A (2026)

Twenty Years of the Concept of the Privileged Extracellular Region: From Early Computations to Modern Anatomical Evidence.

Journal of neurochemistry, 170(11):.

The brain extracellular space (ECS) is a heterogeneous and plastic compartment. The concept of the privileged extracellular region (PER) was introduced in 2004 as a computationally derived, spatially restricted microdomain of the ECS immediately surrounding glial cells, within which potassium (K[+]) accumulates preferentially and independently from the broader extracellular milieu. Using mathematical modeling of membrane currents in astrocytes and oligodendrocytes, the seminal paper demonstrated that the volume of the ECS accessible for K[+] accumulation during depolarization was 10-100-fold smaller around oligodendrocytes than around astrocytes, establishing the first quantitative evidence for spatial heterogeneity of the periglial ECS. Over the following two decades, converging lines of structural, functional, and clinical evidence have dramatically expanded this concept. Perisynaptic astrocytic regions and extracellular geometry have now been visualized at nanoscale resolution using STED, dSTORM, and super-resolution shadow imaging (SUSHI), revealing a spongiform architecture with fine leaflets and reflexive loops that delineate functionally distinct microdomains at the synaptic interface. EAAT2/GLT-1 glutamate transporters and Kir4.1 K[+] channels concentrated within these processes provide the molecular infrastructure for localized neurotransmitter clearance and K[+] siphoning. Disruption of PER geometry-through reactive gliosis, astrocytic atrophy during aging, or leaflet retraction-contributes to the pathophysiology of epilepsy, Alzheimer's disease, ischemia, and cognitive decline. The present review traces the intellectual lineage of the PER concept, integrates two decades of anatomical and functional evidence, and highlights the therapeutic implications of understanding periglial microdomains as active regulators of brain homeostasis.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Gelenter MD, Ying J, Anfinrud PA, et al (2026)

Small-Molecule Contacts to NMR-Invisible Aβ40 Oligomers Revealed by Pressure-Jump NMR and t1-Noise Suppression.

Journal of the American Chemical Society, 148(45):48777-48781.

Soluble amyloid-β (Aβ) oligomers are widely implicated as neurotoxic species in Alzheimer's disease but remain difficult to characterize because their transient, heterogeneous assemblies are effectively invisible to conventional solution nuclear magnetic resonance (NMR) spectroscopy. Hydrostatic pressure (∼2.2 kbar) dissociates Aβ40 oligomers into monomers with sharp, intense resonances. Here, we exploit this pressure-dependent behavior to detect weak intermolecular contacts formed between small molecules and the NMR-invisible oligomers and read them out after pressure-induced dissociation. Using dimethyl sulfoxide (DMSO) as a simple small-molecule probe, we combine pressure-jump NMR with NOE difference spectroscopy to obtain residue-resolved DMSO-to-Aβ40-oligomer contacts. Because the resulting NOE signals are very weak, their detection requires substantial suppression of t1 noise that is shown to arise primarily from minute FID-to-FID phase and frequency instabilities. We therefore introduced RePAIR (Reference-based Phase And frequency Instability Reduction), a software package that uses an internal reference resonance to correct per-FID phase and frequency errors in gradient-encoded, phase-modulated data sets, suppressing t1 noise and revealing otherwise hidden intermolecular NOEs. The resulting contact profile shows preferential DMSO interactions with the ordered, hydrophobic β-sheet core of the Aβ40 oligomers. More broadly, this approach provides a framework for obtaining residue-resolved information on weak small-molecule interactions with transient protein assemblies that are otherwise inaccessible to conventional solution NMR.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Moon E, Radelof C, Sticht J, et al (2026)

Glycosaminoglycans Promote Amyloid-β Aggregation via Multivalent, pH-Dependent Interactions.

Journal of the American Chemical Society, 148(45):49109-49120.

Glycosaminoglycans (GAGs) are polyanionic polysaccharides that colocalize with amyloid deposits in Alzheimer's disease, yet their mechanistic contribution to aggregation remains unclear. Here, we show that GAGs function as pH-responsive electrostatic scaffolds that selectively accelerate Aβ(1-42) aggregation under mildly acidic, early endosomal-like conditions but not at neutral pH. Combining experimental and computational approaches, we identify protonated N-terminal histidines as key determinants of GAG binding. Weak interactions between GAGs and the charged N-terminal region of Aβ promote conformational rearrangements that bring peptides into proximity and expose adjacent hydrophobic aggregation-prone segments, thereby facilitating peptide clustering. Kinetic analyses reveal that aggregation is enhanced in a way consistent with an apparent increase in effective peptide concentration, accelerating nucleation without altering the dominant aggregation pathway. Systematic variation of GAG chain length and sulfation level further demonstrates that aggregation enhancement requires a threshold degree of multivalency, consistent with a clustering-driven mechanism. Together, these findings establish a framework in which pH-dependent polyelectrolyte interactions act as molecular triggers of amyloid nucleation and define the physicochemical parameters that govern when GAGs transition from passive interaction partners to active promoters of Aβ aggregation, providing insight into how cellular microenvironments may regulate the earliest stages of Alzheimer's disease pathology.

RevDate: 2026-11-19

Na S, Kim HS, Kim GH, et al (2026)

Corrigendum to 'Memantine in Korean Alzheimer's disease: A prospective real-world REMIND study' [Int. Psychogeriat. (2026) 100298].

RevDate: 2026-11-19
CmpDate: 2026-11-19

Chu C, Wang Y, Jin L, et al (2026)

Development and validation of interpretable multidomain models for multi-pathology prediction in Alzheimer's disease and related dementias.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Mixed neuropathology is common in Alzheimer's disease (AD) and related dementias (ADRD), yet joint prediction using multidomain predictors remains limited.

METHODS: We analyzed 1463 autopsied participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) and externally validated the models in 2613 participants from the National Alzheimer's Coordinating Center (NACC). The primary model was an explainable boosting machine classifier chain predicting seven neuropathologic outcomes. Complementary epidemiologic analyses examined four neuropathologic pathways, isolated versus mixed multi-pathway profiles, and inter-pathology dependence.

RESULTS: Mixed neuropathology was common and heterogeneous. Outcome prevalence ranged from 9.6% to 65.1% in ROSMAP and from 15.6% to 68.3% in NACC. In ROSMAP, the macro-averaged area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) were 0.80 (95% confidence interval [CI], 0.74-0.82) and 0.70 (95% CI, 0.65-0.77), respectively; outcome-specific AUROCs ranged from 0.78 to 0.83, AUPRCs from 0.56 to 0.87, and Brier scores from 0.07 to 0.12. In NACC, corresponding macro-averaged AUROC and AUPRC were 0.77 (95% CI, 0.74-0.79) and 0.68 (95% CI, 0.66-0.70), respectively; outcome-specific AUROCs ranged from 0.72 to 0.80, AUPRCs from 0.54 to 0.84, and Brier scores from 0.10 to 0.13. Predictor contributions showed shared and pathology-specific patterns. The 15-predictor model provided a lower burden alternative with reduced performance.

DISCUSSION: Interpretable multi-label prediction using multidomain predictors may help characterize the heterogeneity of mixed neuropathology in AD/ADRD. Prospective evaluation in diverse populations is warranted to assess generalizability.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Lu QS, Ma L, Jiang WJ, et al (2026)

Correction to: KAT7/HMGN1 signaling epigenetically induces tyrosine phosphorylation-regulated kinase 1A expression to ameliorate insulin resistance in Alzheimer's disease.

World journal of psychiatry, 16(4):117493.

[This corrects the article DOI: 10.5498/wjp.v14.i3.445.][This corrects the article on p. 445 in vol. 14, PMID: 38617985.].

RevDate: 2026-11-19
CmpDate: 2026-11-19

Jiménez-Lozano S, Peña-Guzmán D, Badillo-Carrasco A, et al (2026)

Olea europaea-derived interventions and cognitive outcomes across cognitive aging, mild cognitive impairment, and Alzheimer's disease: a systematic review of controlled clinical studies.

Frontiers in nutrition, 13:1981425.

BACKGROUND: Olive-derived nutritional exposures range from phenolic-rich extra-virgin olive oil (EVOO) to refined oils, olive-leaf preparations, and isolated bioactives, but these matrices are frequently treated as interchangeable despite major compositional and physiological differences.

OBJECTIVE: To systematically evaluate controlled human evidence relating oral Olea europaea-derived interventions to cognitive outcomes across cognitive aging, mild cognitive impairment (MCI), and Alzheimer's disease (AD), while distinguishing direct efficacy trials from broader dietary-pattern interventions and trials in which olive oil served as an active comparator.

METHODS: PubMed, Web of Science, and ClinicalTrials.gov were searched through 26 January 2026 and updated through 18 September 2026. Eligible reports contained a controlled human comparison involving an Olea-derived oral exposure or an olive-oil comparator and reported validated cognitive outcomes. Because the included studies represented different causal contrasts, intervention matrices, populations, instruments, and reporting structures, findings were synthesized narratively. Risk of bias and certainty of evidence were assessed using Cochrane RoB 2 and GRADE, respectively.

RESULTS: Thirteen reports representing 12 randomized intervention cohorts were included. Three reports directly tested an Olea-derived intervention, three evaluated EVOO within broader Mediterranean-diet interventions, and seven used olive oil primarily as the comparator for another bioactive intervention. Direct trials reported isolated, outcome-specific differences in ADAS-Cog, blood-brain barrier permeability, functional connectivity, and MMSE preservation, but these findings were inconsistent across global cognition, domain-specific measures, functional outcomes, and biological endpoints. Dietary-pattern findings could not isolate EVOO, whereas active-comparator trials estimated the effects of non-olive interventions relative to heterogeneous olive-oil controls. Three reports were judged at high risk of bias and the remaining ten raised some concerns; none was judged at low overall risk. Certainty was low to very low for most direct and dietary-pattern outcomes.

CONCLUSIONS: Olea europaea-derived interventions should not be interpreted as a single therapeutic entity. Controlled evidence is sparse, heterogeneous, and predominantly of low or very low certainty. Selected studies report outcome-specific signals consistent with cognitive preservation or biological target engagement, but these findings do not establish clinical efficacy for the prevention or treatment of cognitive decline, MCI, or AD. Compositionally defined, adequately powered trials with prespecified clinically meaningful cognitive and functional outcomes are required before clinical recommendations can be made.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Petrisko TJ, Chu SH, Gomez-Arboledas A, et al (2026)

Timing of global C1q deletion differentially regulates cognition and pathology in a mouse model of Alzheimer's disease.

Frontiers in immunology, 17:1993961.

The complement system, while having protective roles in the CNS, contributes to enhanced inflammation and cognitive decline in Alzheimer's disease (AD). C1q, is required for the initiation of the classical complement cascade but also has multiple roles that are independent of the rest of the complement cascade. Previous reports showed that constitutive global deletion of C1q reduces glial activity and attenuates neuronal loss in AD mouse models with no effect on plaque load. In a separate study young adult deletion of C1q specifically in microglia resulted in improved spatial memory performance in the more aggressive Arctic (Arc) AD mouse model again without changes in plaque accumulation. Here we used the Arc model containing floxed C1qa gene with or without RosaCre[ERT2] to determine if there were benefits when C1q was deleted globally in adulthood before robust amyloid accumulation or after substantial amyloid plaque accumulation vs C1q-sufficient Arc. Mice were treated with tamoxifen at either 11-wks or 20-wks of age to induce global C1q deletion. Spatial memory was tested prior to collecting brains at 10m of age. Brain sections were stained for C3/GFAP and C5aR1/Iba1 as a measure of glial activation. Superresolution microscopy was utilized to assess synaptic density of Vglut1-Psd95 synapses while confocal microscopy was used to quantify the engulfment of Vglut1 by microglia and amyloid by microglia and astrocytes. In summary, young adult global deletion of C1q in a mouse model of amyloidosis results in improved cognitive function, decreased synaptic pruning, reduced amyloid plaque accumulation and reduced astrocytic C3 expression, whereas deletion of C1q after substantial plaque deposition shows reduced C3 expression but only slight nonsignificant rescue of synaptic density, no change in amyloid accumulation and no improvement in cognitive function relative to the C1q-sufficient Arc at 10 mo of age. These findings support the role of C1q in synapse engulfment and astrocyte C3 induction and are also consistent with the hypothesis that peripheral C1q can contribute to amyloid plaque load, either directly or by modulating peripheral inflammation. The results also suggest a limited effective treatment window for targeting C1q for preservation of cognitive function.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Aguado C, Alfaro-Ruiz R, Martínez-Poyato ML, et al (2026)

Synaptic and extrasynaptic SK2 channels are differentially altered in the hippocampus in Aβ pathology.

Frontiers in neuroanatomy, 20:1974708.

Calcium signaling mediated by small-conductance calcium-activated potassium (SK) channels plays a critical role in regulating synaptic plasticity and neuronal excitability in the hippocampus. Although SK2 channels are strategically positioned to control calcium-dependent feedback mechanisms, their subcellular organization in Aβ pathology remains poorly understood. Here, we investigated the expression and nanoscale distribution of SK2 channels in the hippocampus of APP/PS1 mice. Using histoblot analysis, we found that overall SK2 protein levels, including the synaptically targeted SK2-L isoform, were not significantly altered in APP/PS1 mice compared with age-matched controls. In contrast, high-resolution SDS-digested freeze-fracture replica labeling revealed a marked and compartment-specific redistribution of SK2 channels. Quantitative analyses demonstrated a significant increase in extrasynaptic SK2 immunoparticles along dendritic membranes, whereas synaptic SK2 localization at postsynaptic densities remained largely preserved. These findings indicate a clear dissociation between SK2 expression and subcellular organization in Aβ pathology. Rather than altering total protein levels, AD selectively remodels the spatial distribution of SK2 channels, preferentially affecting dynamic extrasynaptic pools. This redistribution may have important consequences for the regulation of intrinsic membrane excitability and synaptic integration in hippocampal circuits. More broadly, our results support the concept that disruption of membrane protein organization at the nanoscale level represents a key mechanism underlying early neuronal dysfunction in Aβ pathology.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Rhee HY, Lee MB, Kim HM, et al (2026)

High-frequency conductivity was negatively associated with myelin water fraction in the brain of cognitive impairments.

Frontiers in aging neuroscience, 18:1923437.

BACKGROUND: Alzheimer's disease (AD) and mild cognitive impairment (MCI) are associated with cognitive decline and brain changes, including gray and white matter atrophy. High-frequency conductivity (HFC) and myelin water fraction (MWF) serve as potential biomarkers for these neurological changes.

PURPOSE: To evaluate the relationship between HFC and myelin-related metrics (MWF and white matter volume (WMV)) in the context of cognitive decline.

MATERIALS AND METHODS: This cross-sectional prospective study included 170 participants who were differentially diagnosed as 42 cognitively unimpaired (CU) older participants, 84 with amnestic MCI, and 44 with clinically diagnosed probable AD of mild to moderate severity. MRI techniques were used to measure HFC, MWF, and WMV across defined regions of interest that were (1) voxels with a WMV value greater than 1% and an MWF value greater than 1% (whole brain), (2) the hippocampus, (3) the insula, and (4) the thalamus in each participant. Statistical methods included correlations between these indices and clinical measures, multiple regression analyses of HFC with other MRI indices, and receiver operating characteristic (ROC) curve analysis.

RESULTS: The robust multiple regression analyses showed that HFC was negatively associated with MWF in the whole-brain, hippocampal, and insular ROIs. Associations between HFC and WMV were region-specific, with a negative association in the whole-brain ROI and a positive association in the insula. Probable AD showed higher HFC in the whole-brain, hippocampal, and thalamic ROIs, while group differences in MWF and WMV were region-specific.

CONCLUSION: Lower apparent MWF was associated with higher HFC, suggesting a relationship between tissue microstructural alterations and conductivity. Further research is needed to validate these findings in diverse populations.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Roy S, Biswas S, Guha D, et al (2026)

In silico characterization of the protein Aβ175 from circular RNA CircAβ-a and its involvement in the pathogenesis of Alzheimer's disease (AD).

Frontiers in bioinformatics, 6:1979627.

Circular RNAs are specialized single-stranded molecules having covalently closed termini. They were once thought to be mere transcriptional artefacts. However, they have now been identified as significant players in tumorigenesis, neurodegeneration and other diseases. Though generally classified as non-coding, certain circular RNAs demonstrate the ability to encode proteins, reshaping our understanding of their biological roles. CircAβ-a, a circRNA that contains the amyloid beta (Aβ)-coding region of the APP gene, acts as an alternative source of Aβ peptides. The discovery of circAβ-a suggests that Aβ peptides can be generated through a non-canonical translation mechanism, independent of APP processing and that Aβ peptides are the key contributors to Alzheimer's Disease pathogenesis. CircAβ-a is efficiently translated into Aβ175, which is further processed into Aβ peptides. Inhibiting circAβ-a translation or modifying its expression might help in reducing Aβ accumulation in brain. To develop effective inhibitors for Aβ peptides, it is crucial to understand its structural characteristics, functional properties and interaction patterns. This study focuses on characterizing the Aβ175 protein by predicting its structural features to explore its potential as an alternative biomarker, which can be verified through wet-lab experiments, for the treatment of Alzheimer's Disease.

RevDate: 2026-11-19
CmpDate: 2026-11-19

She L, Wu J, Xue Y, et al (2026)

Prediction of multi-stage Alzheimer's disease progression based on surface-based morphometry and machine learning.

Frontiers in aging neuroscience, 18:1957171.

BACKGROUND: Early identification of individuals at high risk of progression from normal cognition (NC) to mild cognitive impairment (MCI) and from MCI to Alzheimer's disease (AD) is crucial for timely intervention. However, predictive models that simultaneously address multiple transition stages along the AD continuum remain limited.

OBJECTIVE: To develop and validate machine learning models and nomograms based on surface-based morphometry (SBM) features, neuropsychological assessments, and plasma biomarkers for predicting disease progression in early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and NC populations.

METHODS: This longitudinal study included 406 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. SBM features, including sulcal depth, gyrification index, and fractal dimension, were extracted from 3D T1-weighted MRI. Multiple machine learning classifiers (support vector machine, linear discriminant analysis, LASSO, and Gaussian process) were employed to construct predictive models. An R score generated from the optimal machine learning model was combined with clinical predictors via logistic regression to build the nomogram. Model performance was assessed using receiver operating characteristic (ROC) curves.

RESULTS: The study included 406 participants: 150 with EMCI, 67 with LMCI, and 189 with NC. The conversion rates to the next stage were 20.7% for EMCI-to-AD, 49.3% for LMCI-to-AD, and 26.5% for NC-to-MCI. The SBM-based machine learning models yielded AUCs of 0.769, 0.750, and 0.640 for predicting conversion from EMCI to AD, LMCI to AD, and NC to MCI, respectively, in the validation set. The integrated nomogram incorporating the R score and clinical predictors significantly improved predictive performance, achieving validation AUCs of 0.91 (EMCI to AD), 0.74 (LMCI to AD), and 0.73 (NC to MCI). Independent predictors for the different transition stages included the R score, tau protein (P-tau181), Aβ42/Aβ40 ratio, age, and Montreal Cognitive Assessment (MoCA) score, with variation across stages.

CONCLUSION: Integrating the SBM-derived R score with clinical and biomarker data through a nomogram provides a clinically interpretable tool for predicting multi-stage AD progression. This strategy may facilitate early risk stratification and the development of individualized intervention plans.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Kesavamoorthy N, Briski N, Zaidi S, et al (2026)

Donanemab-Associated Amyloid-Related Imaging Abnormalities Presenting as Acute Stroke Mimic and Seizure.

Clinical case reports, 14(11):e73881.

Amyloid-related imaging abnormalities may present as stroke mimics or seizures in patients receiving anti-amyloid therapy. Prompt recognition and urgent MRI evaluation are essential to avoid potentially harmful interventions, including inappropriate thrombolysis. Anti-amyloid therapy should be withheld, and corticosteroids may be considered in severe or symptomatic cases.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Zhang J, Hou X, Zhang L, et al (2026)

Spatial regulation of phospholipid peroxidation by endoplasmic reticulum-mitochondria contact sites: implications for neuronal ferroptosis in Alzheimer's disease.

Frontiers in aging neuroscience, 18:1992424.

Ferroptosis-related alterations have been reported in Alzheimer's disease (AD), but where neuronal phospholipid peroxidation begins and how it propagates between organelles remain unclear. Endoplasmic reticulum-mitochondria contact sites coordinate phospholipid exchange and influence local redox processes, potentially regulating the spatial distribution of this damage. Evidence from non-AD experimental systems implicates contact-associated membranes in early phospholipid peroxidation. Specific contact-associated pathways can also transfer lipid radicals from mitochondria to the endoplasmic reticulum, alleviating mitochondrial oxidative damage. AD models have separately shown alterations in contact structures and membrane lipid composition, while postmortem human brain tissue also exhibits contact-associated phenotypes. However, these observations have not been directly linked causally to the spatiotemporal dynamics of phospholipid peroxidation and ferroptotic outcomes within the same AD-relevant neuronal system. Based on this evidence, we propose a working hypothesis requiring validation. AD-associated contact remodeling may alter the local supply of oxidizable phospholipids and the interorganelle distribution of lipid radicals, thereby influencing neuronal phospholipid peroxidation and ferroptosis susceptibility. This hypothesis can be tested in AD-relevant neuronal models by jointly measuring contact structures, lipid exchange flux, and the subcellular location and temporal sequence of phospholipid peroxidation. These measurements should be combined with pathway-specific interventions and ferroptosis rescue experiments. If these causal relationships are validated, this framework could provide a mechanistic basis for identifying neuronal membrane lipid oxidation biomarkers and preclinically evaluating candidate contact-site-associated intervention targets.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Montaña-Valverde G, Martínez-Molina N, Aquilué-Llorens D, et al (2026)

Disruptions in brain hierarchical organization reveal Alzheimer's disease progression.

Brain communications, 8(6):fcag425.

Alzheimer's disease arises from interacting amyloid, tau and neurodegenerative processes and is associated with large-scale network dysfunction and reduced brain dynamics complexity. However, it remains unclear whether disease progression alters the causal hierarchical organization of large-scale brain dynamics. We examined hierarchical brain organization across the Alzheimer's disease continuum using multimodal neuroimaging from 134 participants in the Alzheimer's Disease Neuroimaging Initiative (46 amyloid-negative cognitively normal, 36 amyloid-positive cognitively normal, 31 amyloid-positive mild cognitive impairment and 21 amyloid-positive Alzheimer's disease dementia; mean age 73.9 ± 6.2 years). Participants underwent resting-state functional magnetic resonance imaging and positron emission tomography, with amyloid and tau imaging available in 121 individuals. We estimated the generative effective connectivity using whole-brain modelling and quantified hierarchy through trophic levels and directedness using an ecology-inspired framework. Group differences were assessed using non-parametric permutation testing with covariate adjustment and false discovery rate correction. A supervised machine learning framework using logistic regression with nested cross-validation and Monte Carlo resampling evaluated whether hierarchical features could classify disease stage. Associations with amyloid, tau burden and grey matter volume and cognitive performance were examined using mixed-effects ridge regression and multiple linear regression adjusted for age, gender, education and APOE-ɛ4 carrier status. Amyloid-negative cognitively normal exhibited a well-stratified hierarchy in which somatomotor and frontoparietal regions acted as sources, the default mode network occupied an intermediate integrative position, and memory, limbic and visual systems acted as sinks. Across the clinical spectrum, we observed a progressive flattening of hierarchical organization, characterized by reduced trophic levels in the somatomotor, salience, control and default mode networks, and increased hierarchical positioning of visual and thalamic regions. Hierarchical features classified disease stage, including the preclinical distinction between amyloid-negative and amyloid-positive cognitively normal, indicating sensitivity to early stages. Hierarchical alterations were associated with amyloid, tau and neurodegeneration. Moreover, they predicted cognitive impairment across all clinical tests. These findings suggest that Alzheimer's pathology selectively disrupts hierarchical brain organization. Our ecology-inspired framework offers a sensitive, non-invasive approach linking molecular pathology to large-scale network reconfiguration and cognitive decline, providing additional information beyond conventional correlation-based or graph-theoretical metrics, revealing its potential as a neuroimaging marker for early detection and disease staging across the Alzheimer's continuum.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Buyuksandalyaci Tunc E, Park M, Kansara R, et al (2026)

The Growing Role of Glucagon-Like Peptide-1 Receptor Agonists in Neuropsychiatry.

Clinical pharmacology : advances and applications, 18:580850.

The co-occurrence of metabolic and psychiatric disorders poses a major challenge in medicine, and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as candidates for neuropsychiatric repurposing given the wide distribution of glucagon-like peptide-1 (GLP-1) receptors in brain regions governing mood, cognition, and reward. This narrative review summarizes central and peripheral mechanisms linking GLP-1 signaling to neuropsychiatric outcomes, critically appraises clinical evidence across psychiatric and neurodegenerative domains, and proposes a framework for integrating GLP-1RAs into neuropsychiatric care. A targeted search of PubMed/MEDLINE and ClinicalTrials.gov (January 2015-August 2026) prioritized randomized controlled trials, meta-analyses, and prospective cohorts reporting neuropsychiatric outcomes. Four converging mechanisms- neuroinflammation, metabolic-vascular neuroprotection, synaptic plasticity, and mesolimbic reward modulation- underpin this rationale. The strongest and most clinically actionable evidence supports GLP-1RA use for antipsychotic-induced metabolic dysfunction, with trials in clozapine/olanzapine-treated patients showing substantial weight loss and glycemic normalization without psychiatric worsening or altered clozapine levels. By contrast, in Alzheimer's disease, despite consistent observational signals of 33-53% dementia risk reduction, Phase 3 EVOKE/EVOKE+ trials found no benefit of oral semaglutide in early symptomatic disease despite biomarker engagement, favoring a prevention- rather than treatment-focused framework. Evidence in Parkinson's disease and major depressive disorder remains more limited: motor benefit in Parkinson's disease appears restricted to short-acting agents, with the largest phase 3 trial negative, while broad antidepressant efficacy is unsupported, although semaglutide improved effort-based decision-making in anhedonic, metabolically burdened patients. Additional signals exist for alcohol use disorder, binge eating disorder, and obstructive sleep apnea. Psychiatric safety appears reassuring across meta-analyses of over 133,000 participants, though exclusion of psychiatric populations from pivotal trials limits generalizability. Current evidence supports selective, investigational use of GLP-1RAs in neuropsychiatric care- most robustly for antipsychotic-induced metabolic dysfunction- rather than generalized repurposing, pending adequately powered trials with neuropsychiatric endpoints, structured monitoring, and equitable access strategies.

RevDate: 2026-11-19

Vyshedskiy A, Tagliavia A, Kermen R, et al (2026)

Weekly assessments of global cognition using the digital Boston Cognitive Assessment (BoCA): Adherence to protocol, practice effects, and MDC.

Applied neuropsychology. Adult [Epub ahead of print].

There is increasing evidence that lifestyle interventions and pharmacological treatment can help prevent or delay cognitive decline and dementia, including Alzheimer's disease. However, early identification of the disease remains a major clinical challenge. Reliable detection at preclinical stage requires repeated longitudinal cognitive assessments; yet traditional paper-and-pencil tests offer a limited number of alternate versions, leading to practice effects that can mask true cognitive changes. In contrast, digital cognitive assessments provide essentially unlimited test variability and can be self-administered, reducing complexity and the cost of longitudinal monitoring. The Boston Cognitive Assessment (BoCA) is a validated, self-administered, 10-minute digital measure of global cognition across eight core domains, that employs randomly selected, non-repeating tasks to avoid practice effects. This study aimed to evaluate participant adherence to the weekly self-assessment protocol and to quantify BoCA's practice effects and Minimal Detectable Change. Volunteers (n = 100; mean age 61.0 ± 15.7 years) were instructed to complete BoCA weekly without reminders or monetary compensation. Most inter-test intervals clustered around 7 days, indicating strong adherence to the weekly schedule. BoCA demonstrated no statistically significant practice effects (p = 0.557) and excellent long-term reliability (ICC = 0.81). These findings support BoCA as a practical tool for longitudinal monitoring of global cognition.

RevDate: 2026-11-19

Sekhon H, Sukhu A, Fallavollita P, et al (2026)

Nature-Based Virtual Reality for Depression in Alzheimer's Disease: Protocol of a Pilot Randomized Controlled Trial.

Gerontology pii:9102355 [Epub ahead of print].

INTRODUCTION: Alzheimer's disease (AD) is the most common form of dementia. Depression is common in AD, with limited evidence for the efficacy of pharmacotherapy. Limited in-home non-pharmacological treatments for depression in AD underscore a need for novel in-home treatments. Virtual reality (VR) is an immersive audiovisual technology that has been used in different clinical contexts. Exposure to nature can improve mental health, including the behavioral and psychological symptoms of dementia. To our knowledge, in-home VR use has not been assessed in AD with depression (AD-D). This study aims to assess the feasibility of an in-home nature VR (N-VR) exposure versus an active non-immersive control intervention for individuals with AD-D.

METHODS: This is a pilot, parallel group, assessor-blinded, randomized controlled trial assessing an N-VR for AD-D. Participants (n = 50) with AD-D are randomized (1:1) to N-VR versus an active control intervention of nature-based videos. All participants receive the intervention as 15-min sessions delivered twice a week, for 4 weeks. Assessments are conducted remotely by assessors (via WebEx) blinded to randomized assignment at baseline, after each session, and within 7 days of completing the 4-week course to assess tolerability, feasibility, and acceptability. Participants also have the option to participate in a focus group at the end of the study.

CONCLUSION: Measures of feasibility, tolerability and acceptability, and preliminary clinical outcomes will be compared between the VR and control groups in intention-to-treat analyses. Qualitative data from the focus group is thematically analyzed. Relevant participant characteristics (e.g., age, sex, and baseline clinical characteristics) will be described across groups and may be considered in exploratory or sensitivity analyses, recognizing the limited statistical power of this pilot study.

DISCUSSION: If successful, this study has the potential to establish the feasibility of remote VR for individuals with AD-D.

RevDate: 2026-11-19

Barro M, Martínez AL, Moreira D, et al (2026)

Development of a novel neuronal phenotypic in vitro model of familial Alzheimer's disease using the human neuroblastoma-derived immortalized SH-SY5Y cell line.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disorder and the leading cause of dementia. Despite its undeniable effect on current society, it remains one of the diseases for which clinical trials have the highest failure rate, and therapeutic interventions remain palliative, thus creating an unmet demand to develop translational models that can accelerate pre-clinical drug discovery.ObjectiveWe aimed to develop a scalable neuronal phenotypic model using differentiated SH-SY5Y cells with mature neuronal phenotypes.MethodsSH-SY5Y were differentiated by exposure to either retinoic acid and phorbol 12-myristate 13-acetate or retinoic acid and GLP-1. Cells differentiated with retinoic acid and GLP-1 were transfected with APP V717I and MAPT P301L mutants. Mutation-induced morphological alterations were measured by immunocytochemistry and neuron activation through intracellular calcium accumulation.ResultsTransfection induced alterations, including reduced cell densities, neurite lengths, and dendritic arborization, together with increase of amyloid-β (Aβ) aggregation and ROS activity, which are compatible with the neurodegenerative changes observed in AD. A physiological assay based on intracellular calcium imaging revealed hypoexcitability in transfected cultures, suggesting a neurodegenerative process compatible with the later stages of the disease. Treatment of cell cultures with the reference neuroprotective compounds melatonin and resveratrol exerted a significant restorative effect on the morphophysiological variables studied.ConclusionsTherefore, we introduce a novel, miniaturized, and automatable in vitro AD model that enables studies on the neurodegenerative mechanisms related to the disease and supports high-throughput screening assays for pre-clinical drug discovery.

RevDate: 2026-11-19

Dhana K, Cherian LJ, Yang D, et al (2026)

Association of the Area Deprivation Index with cognitive function in individuals with acute ischemic stroke.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundNeighborhood socioeconomic disadvantage is associated with lower cognitive function, but whether this association persists in individuals with acute ischemic stroke is unclear.ObjectiveTo assess whether the Area Deprivation Index (ADI) is associated with global and domain-specific cognition in individuals with acute ischemic stroke.MethodsThe Nutrition Effects on Brain Outcomes and Recovery in Stroke after Hospitalization (NOURISH) study enrolled 266 patients with ischemic stroke aged 55 years and older. ADI is an area-level composite measure derived from 17 U.S. Census indicators spanning education, employment, income, poverty, and housing quality. Cognitive function was assessed using a standardized neuropsychological battery comprising 19 cognitive tests, from which global cognition and five cognitive domains were computed.ResultsAmong the 266 participants included in the analysis, 152 (57.1%) were women and 159 (59.8%) were Black individuals. The mean age was 68.3 years (SD = 8.0). Higher ADI at both the state and national levels was associated with lower global cognitive z-scores; each 1-decile increase in State ADI rank was associated with a 0.044-unit lower global cognitive z-score (β = -0.044; SE = 0.017; p = 0.010), and each 10-percentage-point increase in National ADI rank was associated with a 0.056-unit lower global cognitive z-score (β = -0.056; SE = 0.020; p = 0.005). Higher ADI rank was also associated with lower executive function, episodic memory, and perceptual speed.ConclusionsNeighborhood socioeconomic disadvantage, as measured by ADI, was associated with lower cognitive function in individuals with acute ischemic stroke.Trial RegistrationClinicalTrials.gov Identifier: NCT04337255.

RevDate: 2026-11-19

Wang K, Zhou X, Chen Y, et al (2026)

Cerebrospinal fluid dynamics associated with neurovascular coupling and cognitive and depressive symptoms in cerebral small vessel disease.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundDepressive symptoms and cognitive decline are common in cerebral small vessel disease (CSVD) and linked to abnormal cerebrospinal fluid (CSF) dynamics, but mechanisms remain unclear.ObjectiveTo investigate whether neurovascular coupling links CSF dynamics dysfunction to cognitive and depressive symptoms in CSVD.MethodsWe enrolled 317 CSVD patients and 95 healthy controls. Neurovascular coupling was assessed using correlations between cerebral blood flow (CBF) and resting-state functional measures: fractional amplitude of low-frequency fluctuations (fALFF) and regional homogeneity (ReHo). CSF dynamics were evaluated using diffusion tensor imaging-analysis along the perivascular space (DTI-ALPS).ResultsDTI-ALPS was reduced in CSVD, with decreased global and regional CBF-fALFF coupling. Greater depressive (β = -0.200, 95% CI: -0.326 to -0.074) and anxiety severity (β = -0.254, 95% CI: -0.382 to -0.126) were associated with lower DTI-ALPS, whereas cognitive performance was positively associated with DTI-ALPS (β = 0.164, 95% CI: 0.049-0.280; all pFDR < 0.05). Cognitive performance positively correlated with whole-brain coupling but not depressive symptoms (β = 0.176, 95% CI: 0.070-0.283; all pFDR < 0.05). DTI-ALPS partially mediated associations between CBF-fALFF coupling and cognitive performance (CBF-fALFF → DTI-ALPS → MMSE: 17.3%; CBF-fALFF (Right Putamen) → DTI-ALPS → MMSE: 20.9%) and showed bidirectional mediation between depressive and cognitive performance (MMSE → DTI-ALPS → HAMD: 18.6%; HAMD → DTI-ALPS → MMSE: 18.9%).ConclusionsNeurovascular coupling dysfunction may contribute to CSF dynamics dysfunction in CSVD. Altered CSF dynamics may bidirectionally mediate cognitive impairment and depressive symptoms, providing mechanistic insight into their co-occurrence.

RevDate: 2026-11-19

Justice K, White DJ, Sly D, et al (2026)

Sleep quality moderating the relationship between hearing loss and cognition in older adults: Implications for Alzheimer's disease risk.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundHearing impairment and poor sleep quality are prevalent, modifiable risk factors for cognitive decline and Alzheimer's disease (AD), but their combined influence on cognition remains unclear.ObjectiveTo examine whether sleep quality modifies the association between hearing impairment and cognitive performance in older adults.MethodsData were drawn from 122 older adults in the MedWalk study. Peripheral hearing (pure-tone average), speech-in-noise (SiN), sleep quality (PSQI), and cognition (CANTAB) were assessed. Generalized linear models tested whether sleep quality moderated associations between hearing and cognition, adjusting for age, sex, and education.ResultsSleep quality moderated these associations, with effects differing by hearing type and cognitive domain. Poorer sleep quality strengthened the association between peripheral hearing loss and associative learning, with greater total errors (Exp(β) = 1.005, p = 0.010) and lower first attempt accuracy (Exp(β) = 0.998, p = 0.021). Poorer sleep quality also strengthened the association between poorer SiN performance and increased spatial working memory errors (Exp(β) = 1.009, p = 0.004) and slower reaction times (Exp(β) = 1.002, p = 0.031). A threshold effect emerged, with poor sleep quality associated with worse associative learning in individuals with moderate-or-greater peripheral hearing loss. Final stratified analysis showed a 15 dB increase in hearing loss was associated with 38.6% more associative learning errors among poor sleepers (PSQI > 5).ConclusionsFindings suggest hearing and sleep quality interact to affect cognition in domain specific ways that are relevant to AD risk. Prospective studies are needed to identify if joint interventions can reduce AD risk.Trial RegistrationThis study was registered with the Australian New Zealand Clinical trials Registry ACTRN12620000978965 (https://www.anzctr.org.au).

RevDate: 2026-11-19

Lu S, Mao H, Rui X, et al (2026)

Neuropathology-defined Alzheimer's disease transcriptomic programs converge in blood at mild cognitive impairment.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundBlood transcriptomic studies in Alzheimer's disease (AD) often train signatures directly in blood, making it unclear whether signals reflect brain disease programs, blood-cell composition, or cohort structure.ObjectiveTo test how neuropathology-defined AD transcriptional programs appear in blood, whether distinct brain programs show a shared peripheral pattern, and whether that pattern is most evident during mild cognitive impairment (MCI).MethodsThree directional gene sets were derived before blood analysis from postmortem brain RNA-seq (GSE278723) to represent amyloid-associated, neurodegeneration-related, and core AD changes. These brain-defined programs were projected into five whole-blood cohorts (1975 participants) using directional single-sample Gene Set Enrichment Analysis and assessed for stage-specific patterns, comparison with size-matched random sets, sensitivity to estimated cell composition, dimensionality, held-out classification, and association with Alzheimer's Disease Neuroimaging Initiative (ADNI) genetic and fluid biomarkers.ResultsBrain-derived AD programs were detected across blood cohorts and showed a shared rather than separable pattern. Scores were highest at MCI, exceeded size-matched random baselines, and were not primarily explained by estimated blood-cell proportions. In GSE63060, P1/P2/P5 scores formed a dominant axis, with PC1 explaining 92.2% of directional half-score variance. A held-out classifier achieved AUC = 0.822, and ADNI analyses showed information beyond APOE ε4 and improved discrimination when blood scores were combined with cerebrospinal fluid pTau181/Aβ42.ConclusionsNeuropathology-defined AD transcriptomic programs form a shared peripheral axis that is most evident at MCI. This brain-anchored signal adds a systemic transcriptional dimension to genetic and fluid biomarkers and provides a biological framework for studying early AD-related disease in blood.

RevDate: 2026-11-19

He Z, Cheng X, Li J, et al (2026)

Venous and glymphatic alterations and their associations with cognition in mild cognitive impairment: A cross-sectional MRI study.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundThe glymphatic system facilitates brain waste clearance along perivascular pathways, which are related to the cerebral venous system. Its dysfunction is increasingly implicated in mild cognitive impairment (MCI) pathogenesis.ObjectiveThis cross-sectional study investigated whether specific venous and glymphatic MRI markers-namely deep medullary veins (DMVs), perivascular spaces (PVS), and the diffusion tensor image analysis along the perivascular space (DTI-ALPS) index-are associated with MCI.MethodsNinety-five participants underwent multi-modal MRI to assess DMVs, PVS, and the DTI-ALPS index. Receiver operating characteristic (ROC) curves evaluated diagnostic discriminative power. Mediation analysis explored whether the DTI-ALPS index mediates the association between DMVs and cognition.ResultsMCI patients showed significantly higher DMVs scores [10 (8, 14) versus 7.5 (6, 10)] and lower DTI-ALPS index (1.23 ± 0.15 versus 1.40 ± 0.21) than cognitively normal (CN) controls (both p < 0.001), whereas PVS did not differ. Combining the DTI-ALPS index and DMVs score yielded an AUC of 0.780 (95% bootstrap CI: 0.669 to 0.864; p < 0.001) for distinguishing MCI. Exploratory cross-sectional mediation analysis suggested that the DTI-ALPS index accounted for the association between DMVs and AVLT-DR (indirect effect β= -0.083, 95% CI = -0.170 to -0.018).ConclusionsConcurrent venous and glymphatic alterations are associated with behaviorally defined MCI. Although combining DMVs and DTI-ALPS did not significantly improve diagnostic accuracy, they provide complementary mechanistic insights, with perivascular transport efficiency accounting for the association between venous impairment and cognition. These markers remain valuable non-invasive tools for MCI screening.

RevDate: 2026-11-19

Jiang X, Jin H, Xu Z, et al (2026)

A coumarin-cyanoisophorone dual-channel probe for imaging H2S/H2O2 redox imbalance in Alzheimer's disease models.

The Analyst [Epub ahead of print].

Hydrogen sulfide (H2S) and hydrogen peroxide (H2O2) are interconnected redox-active species involved in neuronal homeostasis, yet simultaneously visualizing their changes in biological systems remains challenging. Herein, we report DCTE, a spectrally resolved dual-channel fluorescent probe integrating an azide-functionalized coumarin and an arylboronate-functionalized cyanoisophorone through a piperazine linker for simultaneous detection of H2S and H2O2. H2S-mediated azide reduction activates blue fluorescence at 464 nm, whereas H2O2-triggered boronate oxidation produces red emission at 680 nm, enabling distinguishable fluorescence responses with minimal spectral interference. DCTE exhibits high selectivity, rapid response times, and low detection limits. Its favorable photostability and low cytotoxicity further enable dual-channel fluorescence imaging in SH-SY5Y cells, zebrafish larvae, and mouse hippocampal sections. Notably, in okadaic acid-treated SH-SY5Y cells, Aβ1-42-injected zebrafish, and APP/PS1 mouse hippocampal tissues, DCTE consistently revealed decreased H2S-responsive fluorescence accompanied by increased H2O2-responsive fluorescence, indicating characteristic redox alterations associated with Alzheimer's disease (AD). This work establishes a versatile molecular imaging platform for visualizing H2S/H2O2-associated redox alterations and investigating redox dysregulation in AD-related biological models.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Ghazanfari Moghadam S, GH Meftahi (2026)

Whey Protein Hydrolysate Attenuates Spatial Memory Deficits and Alters Hippocampal Keap1/Nrf2/HO-1 in an STZ-Induced Rat Model of Alzheimer's Disease.

Neurochemical research, 51(6):.

Alzheimers disease, known as a primary contributor to dementia, is characterized by cognitive deterioration and the buildup of beta-amyloid plaques along with tau tangles. Oxidative stress is a major contributor to the pathology, and Nrf2 enhances antioxidant responses by activating the HO-1 gene. Whey protein, exhibits antioxidant properties and can activate the Nrf2/HO-1 pathway. This study evaluated the effects of whey protein hydrolysate (WPH) administration on hippocampal-dependent spatial memory, Keap1 and Nrf2 protein expression in hippocampal subregions, HO-1 mRNA expression in whole hippocampal tissue, and hippocampal neuronal integrity in a rat model of STZ-induced Alzheimer's disease.Thirty Wistar rats were assigned to three groups to study Alzheimer's disease induced by a single intracerebroventricular injection of streptozotocin (3 mg/kg). After one week of recovery, the rats received 100 mg/kg of whey protein hydrolysate (WPH) daily via gavage for four weeks. To assess spatial memory, the Barnes Maze test was used. Keap1 and Nrf2 proteins were visualized through immunofluorescent staining; HO-1 gene expression was measured using real-time PCR; and the number of intact hippocampal neurons was counted with cresyl-violet staining. In the WPH group, both latency time and the number of errors decreased, while the duration of stay in the target area increased compared with the STZ group. Also, in the WPH group in the CA1, CA3, and DG regions of the hippocampus, the fluorescence intensity of Keap1 protein decreased, whereas Nrf2 protein levels increased. Additionally, the number of intact neurons in these regions also increased. Our findings reveal that WPH not only alleviates STZ-induced memory impairment but also suppresses oxidative stress by modulating the Keap1/Nrf2/HO-1 pathway. Additionally, it increases the number of intact neurons in the hippocampus.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Ma YN, Tan G, Fan W, et al (2026)

Transplantation of Lhx8/KDM7A/FGF4-induced OM-MSCs-derived neuron-like cells improves neuroinflammation and cognitive impairment in Aβ1-42-induced mouse model.

Journal of bioenergetics and biomembranes, 58(1):.

Cell-based therapies have emerged as a promising therapeutic avenue for Alzheimer's disease (AD). Prior studies have demonstrated the beneficial effects of neuronal-like cells differentiated from human umbilical cord-derived mesenchymal stem cells (MSCs) in mitigating AD pathology. This study investigates the therapeutic efficacy and molecular mechanisms of neuronal-like cells derived from olfactory mucosa MSCs (OM-MSCs) in Aβ1-42-induced acute neurotoxicity. Neuronal differentiation of OM-MSCs was induced using tricyclodecan-9-yl-xanthogenate (D609). An in vivo model was constructed by intrahippocampal injection of Aβ1-42 and treated by transplantation of OM-MSC-derived neuronal cells (OM-MSCs-NCs). In this study, we demonstrated that LIM homeobox protein 8 (Lhx8) expression was upregulated during OM-MSCs-NCs neuronal differentiation. Functional analyses revealed that Lhx8 overexpression enhanced neuronal differentiation of OM-MSCs, whereas Lhx8 knockdown impaired this process. In Aβ1-42-induced mouse models, transplantation of OM-MSCs-NCs ameliorated cognitive deficits, and neuroinflammation while promoting M2-like microglial polarization. Notably, Lhx8-overexpressing OM-MSCs-NCs exhibited amplified therapeutic efficacy, whereas Lhx8-knockdown cells showed diminished effects. Mechanistically, Lhx8 transcriptionally activates lysine demethylase 7 A (KDM7A) by binding to its promoter, thereby regulating the KDM7A/fibroblast growth factor 4 (FGF4) axis. Knockdown of either KDM7A or FGF4 abolished both the pro-differentiation effects of Lhx8 overexpression in vitro and its therapeutic benefits in an Aβ1-42-induced acute toxicity model. In conclusion, Lhx8 promotes neuronal-like differentiation of OM-MSCs by activating the KDM7A/FGF4 axis, thereby alleviating neuroinflammation and cognitive deficits in an Aβ1-42-induced mouse model.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Cai MY, Yang ZH, Zhu LY, et al (2026)

Selenoprotein Network Dysfunction in Neurodegenerative Diseases-Dissecting Brain Distribution, Neuroprotection, and Selenium Supplementation Challenges.

Molecular neurobiology, 63(1):.

Selenium is an essential trace element in humans and, together with 25 selenoproteins, plays a critical role in maintaining central nervous system homeostasis. Alterations in the selenoprotein network are increasingly implicated in multiple neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Although the brain possesses a selenium-prioritization mechanism that preserves selenium under conditions of systemic deficiency, the biological effects of selenium exhibit a U-shaped relationship, whereby both deficiency and excess can result in adverse outcomes. This review systematically summarizes the biosynthesis of selenoproteins and their region-specific distribution, cell-type specificity, and subcellular localization within the brain. Particular emphasis is placed on their central roles in antioxidant defense, neuroprotection, regulation of neuroplasticity, and modulation of neuroinflammation. Furthermore, current evidence is integrated to establish links between selenoprotein biology and the pathological mechanisms underlying neurodegenerative diseases. The major safety challenges associated with selenium supplementation, including its neurotoxicity, as well as the preclinical potential and translational limitations of emerging selenium formulations such as selenium nanoparticles, are also discussed. Notably, although preclinical models suggest neuroprotective effects, large randomized trials have not demonstrated clear clinical benefit, and no selenium formulation has yet been validated for treating neurodegenerative diseases. Current evidence remains insufficient to support clinical recommendations, highlighting the urgent need for precision selenium-based interventions in the future.

RevDate: 2026-11-19

Koh E (2026)

Intersecting Inequities and Solutions in Alzheimer Disease and Related Dementia Care in Connecticut.

Preventing chronic disease, 23:E74 pii:E74.

RevDate: 2026-11-19

Paun O, Lee SY, Kim H, et al (2026)

A chronic grief management intervention-video (CGMI-V) for family caregivers of persons with dementia residing in long-term care: a randomized controlled trial.

Aging & mental health [Epub ahead of print].

OBJECTIVES: Pre-death grief has been increasingly recognized as a core component of the Alzheimer's disease and related dementias (ADRD) caregiving experience. This Stage I randomized controlled trial aimed to evaluate the effects of the 8-week Chronic Grief Management Intervention-Video (CGMI-V) on family caregivers' chronic grief and mental health outcomes (e.g. depressive and anxiety symptoms, and positive states of mind) after they placed their care recipients with ADRD in long-term care facilities.

METHODS: Participants were randomly assigned to either the CGMI-V intervention condition or the minimal treatment (MT) condition and completed assessments at baseline, week 8 (immediately post-intervention), and week 24 (follow-up). We used standardized measures to assess participants' chronic grief levels, depressive and anxiety symptoms, and positive states of mind. All statistical analyses were conducted on an intent-to-treat basis, using linear mixed models.

RESULTS: Our study period largely overlapped with the COVID-19 pandemic. From baseline to 24 wk, compared with caregivers in the MT condition, caregivers in the CGMI-V condition demonstrated a trend toward greater reductions in grief levels, a notable decrease in depressive and anxiety symptoms, and a notable increase in positive states of mind.

CONCLUSIONS: CGMI-V is a promising intervention in support of ADRD family caregivers' chronic grief and mental health after placement in long-term care facilities.

RevDate: 2026-11-19

Miner AE, Stein TD, McKee AC, et al (2026)

Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology.

JAMA pii:2857054 [Epub ahead of print].

IMPORTANCE: Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that cannot accurately be diagnosed during life due to the absence of in vivo biomarkers for CTE neuropathology.

OBJECTIVE: To evaluate plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) as a candidate biomarker for CTE tau tangle neuropathology.

This case series included 21 former American-style football players who completed a blood draw as part of participation in clinical research at Boston University beginning April 17, 2008, and who subsequently died, donated their brain, and had completed autopsy by October 9, 2026.

EXPOSURES: Plasma eMTBR-tau nucleic acid-linked immunosandwich assay single-plex immunoassay and plasma phosphorylated tau 217 (p-tau217) (SP-X n = 20; Elecsys n = 1).

MAIN OUTCOMES AND MEASURES: CTE status and stage. Cumulative neuropathologic tau burden scores ranged from 0 to 33 (higher scores indicate tau burden; 0, no tau burden).

RESULTS: Among 21 male brain donors (median age at blood draw, CTE positive: 68 years [IQR, 61-77]; CTE negative: 49 years [IQR, 47-56]), 18 had a neuropathologic diagnosis of CTE. Of these participants, 16 had a diagnosis of high-stage CTE (stage IV = 8, stage III = 8); and 2, of low-stage CTE (stage II = 1, stage I = 1). Five CTE-positive participants had intermediate or high Alzheimer disease neuropathologic change (ADNC). Plasma eMTBR-tau concentration was significantly higher in CTE-positive participants (median, 0.019 pg/mL [IQR, 0.004-0.030]) compared with CTE-negative participants (0.001 pg/mL [IQR, 0.001-0.001]; β = 1.61 [95% CI, 0.51-2.70]). Plasma eMTBR-tau concentrations were highest among CTE-positive participants with comorbid ADNC (0.082 pg/mL [IQR, 0.059-0.131]) and intermediate among those with high-stage CTE without ADNC (n = 11; median, 0.009 pg/mL [IQR, 0.004-0.021]). Plasma eMTBR-tau concentration was significantly higher in high-stage CTE (median, 0.021 pg/mL [IQR, 0.006-0.038]) compared with low-stage CTE (median, 0.001 pg/mL [IQR, 0.001-0.002]; β = 1.79 [95% CI, 0.45-3.13]) or no CTE (median, 0.001 pg/mL [IQR, 0.001-0.001]; β = 1.78 [95% CI, 0.85-2.71]). Differences remained significant after exclusion of 5 cases with comorbid ADNC. Plasma eMTBR-tau concentration was associated with higher cumulative neuropathologic tau burden score across 11 brain regions (β = 0.71 [95% CI, 0.38-1.05]). Plasma p-tau217 concentration was positively associated with eMTBR-tau (β = 0.68 [95% CI, 0.32-1.04]) but was not associated with CTE. P-tau217 concentrations were in the negative range (n = 11) or intermediate range (n = 5) for participants without ADNC copathology. Four participants with ADNC had p-tau217 concentrations in the positive range; and 1, in the intermediate range.

CONCLUSIONS AND RELEVANCE: Participants with high-stage CTE had higher concentrations of plasma eMTBR-tau than those with low-stage or no CTE; concentrations were highest among those with CTE and comorbid ADNC. Plasma eMTBR-tau may represent a feasible biomarker candidate for high-stage CTE tau tangle neuropathology. Larger autopsy and clinical validation studies are needed to establish overall diagnostic accuracy and specificity of plasma eMTBR-tau for CTE neuropathology, in addition to the associated prognostic and clinical implications.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Su Y, Lu J, Xu J, et al (2026)

Relative Pericentral Tau Distribution in Cerebral Amyloid Angiopathy Compared With Alzheimer Disease.

Neurology, 107(12):e218786.

BACKGROUND AND OBJECTIVES: Differentiating cerebral amyloid angiopathy (CAA) from Alzheimer disease (AD) is essential for prognosis and clinical management. However, pathophysiology-based molecular biomarkers are lacking. Tau deposition may offer discriminative signals: It occurs late in primary cortices including pericentral cortex in AD but may emerge earlier and more diffusely in CAA. We investigated whether a pericentral-predominant pattern of tau deposition distinguishes CAA from AD and characterize its cortical spatial distribution and contributing factors in CAA.

METHODS: We consecutively enrolled healthy controls and patients with CAA and AD with amyloid (18F-florbetapir) and tau (18F-florzolotau) PET. We compared pericentral tau-PET retention (both standardized uptake value ratios [SUVRs] and regional-to-global ratios) between CAA, AD, and controls and identified optimal cutoffs differentiating CAA from AD. We validated the discriminative performance using 18F-flortaucipir tau-PET in an external cohort. We assessed correlates of tau deposition in multivariable regression analyses and analyzed hierarchical patterns of tau involvement using conditional probability analyses in CAA.

RESULTS: The derivation cohort included 22 controls, 80 CAA, and 64 AD (mean age 60.1, 68.4, and 66.3 years; 50.0%, 38.8%, and 50.0% female). The validation cohort included 65 CAA and 19 AD (mean age 74.1 and 73.6 years; 53.8% and 68.4% female). Patients with CAA showed higher global and pericentral tau SUVRs compared with controls but lower than AD. However, pericentral-to-global tau ratios were significantly higher in CAA than AD (0.93 ± 0.07 vs 0.82 ± 0.08, p < 0.001). A cutoff of 0.90 yielded 68.9% (95% CI 58.6-79.6) sensitivity and 87.1% (95% CI 79.1-96.1) specificity in the derivation cohort (AUC = 0.836, 95% CI 0.768-0.904) and 63.1% (95% CI 54.8-71.7) and 94.7% (95% CI 89.5-100), respectively, in the validation cohort (AUC = 0.844, 95% CI 0.747-0.940) for differentiating CAA from AD. In CAA, pericentral tau deposition correlated with regional amyloid deposition (coefficient 0.680, 95% CI 0.489-0.870, p < 0.001) and white matter hyperintensities volume (coefficient 0.001, 95% CI 0.00003-0.001, p = 0.040) and followed parieto-occipital cortices but preceded medial cortex involvement.

DISCUSSION: Higher pericentral-to-global tau ratio differentiates CAA from AD and may reflect spatial distribution patterns potentially influenced by both amyloid and vascular pathology.

RevDate: 2026-11-19

Kim S, Jung YC, Kim E, et al (2026)

Corrigendum to "Right-lateralized cerebellar cortical thickening is associated with mild behavioral impairment in mild cognitive impairment" [J Prev Alzheimers Dis 13 (2026) 100540].

RevDate: 2026-11-19

Murakami T, Yamakuni R, Abe D, et al (2026)

Reduced motor-cortical long-term potentiation-like plasticity reflects amyloid-beta-related synaptic failure in early cognitive decline.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 194:2112467 pii:S1388-2457(26)00968-5 [Epub ahead of print].

OBJECTIVE: Amyloid-beta (Aβ) proteinopathy is a core pathogenic driver of Alzheimer's disease (AD). Although impaired motor-cortical long-term potentiation (LTP)-like plasticity assessed via quadripulse stimulation (QPS) and abnormal cholinergic function evaluated via short-latency afferent inhibition (SAI) correlate with cerebrospinal fluid Aβ42 levels, the relationship between these physiological markers and the spatial distribution of Aβ burden remains unexplored.

METHODS: Thirty-eight right-handed participants with memory complaints underwent amyloid positron-emission tomography (PET) and were stratified into amyloid-positive and amyloid-negative groups based on Centiloid scales (CL). QPS with an interstimulus interval of 5 ms (QPS5) was applied over the left primary motor cortex (M1) to induce motor-cortical LTP-like plasticity. SAI was assessed using transcranial magnetic stimulation over the left M1 coupled with right median nerve stimulation. Motor-evoked potentials were recorded from the right first-dorsal interosseous muscle to evaluate QPS5-induced LTP-like plasticity and SAI.

RESULTS: QPS5 induced LTP-like plasticity in the amyloid-negative group but not in the amyloid-positive group. Conversely, SAI did not differ significantly between the groups. QPS5-induced plasticity correlated negatively with CL values and positively with cognitive performance. Furthermore, QPS5 effects showed significant negative correlations with amyloid-PET signals in the precuneus, cingulate, and medial orbitofrontal cortices.

CONCLUSIONS: QPS5-mediated assessment of motor-cortical LTP-like plasticity serves as a functional marker reflecting Aβ-related neural dysfunction in early-stage cognitive decline. In contrast, the impact of Aβ proteinopathy on central cholinergic systems in the sensorimotor cortex remains minimal at this early stage.

SIGNIFICANCE: Motor-cortical LTP-like plasticity induced by QPS5 is a sensitive functional surrogate for early-stage Aβ-related synaptic dysfunction.

RevDate: 2026-11-19

Danta CC, Bunnell A, Yegambaram M, et al (2026)

Oxytocin analogs as acetylcholinesterase inhibitors: Design, synthesis, and evaluation.

Bioorganic chemistry, 185:110732 pii:S0045-2068(26)01268-X [Epub ahead of print].

Oxytocin (OXT) has demonstrated potential therapeutic effects in Alzheimer's disease (AD) through mechanisms such as reducing amyloid-β (Aβ) accumulation and tau deposition, as well as exerting antioxidant and anti-inflammatory properties. A recent study further revealed that OXT can decrease acetylcholinesterase (AChE) activity in liver and kidney tissues, suggesting that its effects on Aβ and tau pathology may be mediated, at least in part, through AChE inhibition. In addition, 2-aminothiazole derivatives have been reported as potential AChE inhibitors and can be deployed in the treatment of AD. Based on this rationale, a series of 2-aminothiazole based OXT derivatives were designed, synthesized, and evaluated using molecular docking, in vitro AChE inhibition, enzyme kinetics, and antioxidant assays. Docking studies showed that OXT and its analogues fit well within the 20 Å gorge of the AChE active site, engaging both the catalytic active site (CAS) and the peripheral anionic site (PAS). In vitro AChE inhibition assays revealed promising activity, with OXT (Cmpd.16) and Cmpd.4 exhibiting IC50 values of 15.74 μM and 4.1 μM, respectively. Kinetic analysis determined inhibition constants (Kᵢ) of 14.5 μM for Cmpd.16 and 4.5 μM for Cmpd.4, with both compounds following a mixed-type inhibition mechanism. Furthermore, antioxidant evaluations (Cmpd.4; IC50 = 4.33 μM) indicated they may possess potential neuroprotective properties. Compound 4 showed mixed-type AChE inhibition and greater radical-scavenging activity than OXT in the cell-free DPPH assay. Together with the docking results, these findings suggest, but do not establish, a possible dual-site binding mode. Compound 4 can potentially serve as a preliminary peptide-based lead for further optimization and biological validation.

RevDate: 2026-11-19

Lee D, Kim JP, Nho K, et al (2026)

Genetic Variants and Domain-Specific Cognitive Function in the Alzheimer's Disease Continuum: A Systematic Review.

Ageing research reviews pii:S1568-1637(26)00440-X [Epub ahead of print].

BACKGROUND: APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease and is associated with age-related cognitive decline. Whether its association with cognition, and that of other candidate variants, is uniform across cognitive domains or domain-specific remains unclear.

OBJECTIVE: To synthesize single-variant candidate-gene evidence on domain-specific cognitive function (episodic memory, executive function, language, visuospatial function, attention, processing speed) in the Alzheimer's disease-indexed literature, beyond APOE alone.

METHODS: We searched PubMed, Embase, and Scopus on 18 June 2026 without date restriction (PRISMA 2020; PROSPERO CRD420261446003). Of 6,453 records, we included 111 studies; all search strings required an Alzheimer's disease term. We applied two risk-of-bias tools to every study. Two reviewers extracted and appraised data using AI assistance and verified them against the source text, without reporting agreement statistics. Synthesis was narrative by domain, with an exploratory effect-size meta-analysis for APOE.

RESULTS: APOE was examined in 70 of 111 studies (63%), and 30 further genes were examined in two or more studies each. Detrimental APOE associations were most consistent for episodic memory (48 of 75 findings; sign test p=3.3×10⁻⁹) and executive function (28 of 54; p=5.1×10⁻⁴). The direction of association did not differ between domains (χ²(5)=2.13, p=0.83; 84% detrimental), but detection frequency did (null results 28% to 65%; χ²(5)=20.16, p=0.001). In an exploratory meta-analysis of 36 studies, pooled ε4 effects on performance were small and negative in all six domains, significantly so only for episodic memory (Hedges' g=-0.14, 95% CI -0.21 to -0.07; executive function -0.07, -0.13 to 0.00), and within the same studies the episodic memory effect exceeded the executive function and language effects. The episodic memory result was robust to square-root sample-size weighting, age restriction and significance-threshold re-analysis; the executive function result was less robust, and the two risk-of-bias tools disagreed on whether either survives quality stratification.

CONCLUSIONS: The direction of APOE's association with cognition appears uniform across domains; it is detected most often on episodic memory measures, where its standardized effect also exceeds that on executive function and language measures, and part of the between-domain variation in detection, and possibly in effect size, may reflect the instruments used. Evidence beyond APOE is fragmented, with 93 of 123 non-APOE genes (76%) supported by a single study. Single-variant evidence from the Alzheimer's disease literature thus converges on APOE, with only preliminary evidence for a few other Alzheimer's disease risk loci, in contrast to the highly polygenic architecture that genome-wide studies describe for general cognitive function.

RevDate: 2026-11-19

Alok S (2026)

Targeting Microglial Senescence in Brain Ageing and Alzheimer's Disease: Mechanistic Evidence and the Therapeutic Potential of Natural Products.

Ageing research reviews pii:S1568-1637(26)00441-1 [Epub ahead of print].

Microglial senescence is a candidate contributor to brain ageing and Alzheimer's disease, but its identification and therapeutic tractability remain contested. Activation, lysosomal expansion, lipid accumulation and dystrophic morphology do not independently establish senescence. This review critically examines how uncertainty in state identification affects mechanistic interpretation and natural-product evaluation. Genetic perturbation, human induced pluripotent stem cell models and pharmacological studies connect mitochondrial proteotoxic stress, impaired autophagy, DNA damage and sustained inflammatory signalling with senescence-associated microglial phenotypes. Disease-associated and senescence-associated microglial populations are not interchangeable. Delphinidin, andrographolide, resveratrol, honokiol, rosmarinic acid and cycloastragenol reduce senescence-associated readouts in selected experimental systems. Current evidence mainly supports prevention or phenotype modulation; selective microglial senolysis, durable reversal and senescence-dependent cognitive rescue remain unestablished. Functional assessment requires substrate specificity: impaired harmful-substrate disposal can coexist with excessive synaptic engulfment. Translation requires achievable unbound brain exposure, treatment after phenotype establishment and models relevant to human ageing. Circulating inflammatory-marker changes alone cannot demonstrate drug action within microglia or modification of their senescence-associated state. Small, uncontrolled senolytic trials support the feasibility of treatment administration and preliminary pharmacological assessment, but do not establish cognitive efficacy or selective action on senescent microglia. Progress depends on convergent state identification, delayed intervention, lineage-resolved causal experiments and exposure-matched pharmacology. Natural products remain useful mechanistic probes and potential therapeutic leads whose value should be judged by restoration of protective microglial functions and neural outcomes, rather than marker suppression alone.

RevDate: 2026-11-19

Takabayashi K, Andica C, Mahemuti Z, et al (2026)

Baseline diffusion MRI markers of interstitial fluid dynamics are associated with subsequent amyloid conversion in cognitively normal individuals.

NeuroImage pii:S1053-8119(26)00675-0 [Epub ahead of print].

BACKGROUND: Emerging evidence suggests that early disruption of interstitial fluid (ISF) dynamics may precede amyloid-β (Aβ) deposition, and diffusion MRI-derived indices offer noninvasive markers of ISF properties. We investigated whether baseline ISF-sensitive diffusion MRI markers differ between Aβ-negative (-) cognitively normal (CN) individuals who subsequently convert to Aβ-positivity and those who remain Aβ (-), and whether these markers are associated with subsequent Aβ accumulation.

METHODS: We included Aβ (-) CN participants from the Alzheimer's Disease Neuroimaging Initiative cohorts who had baseline MRI and longitudinal amyloid PET. Based on longitudinal amyloid PET standardized uptake value ratio (SUVR), participants were classified as 18 converters who exceeded the Aβ-positivity threshold at least once during follow-up and 16 non-converters who remained Aβ (-) throughout follow-up. Baseline diffusion MRI-derived ISF markers, cortical free water (FW), the diffusion tensor image analysis along the perivascular space (ALPS) index corrected for white-matter microstructural asymmetry (corrected ALPS index), and perivascular space volume fraction, were compared between groups, together with baseline Aβ, tau, and neurodegeneration biomarkers. Associations between baseline MRI measures and annualized change in amyloid PET SUVR were also assessed.

RESULTS: Converters showed higher cortical FW and lower corrected ALPS index than non-converters, despite no baseline group differences in Aβ, tau, or neurodegeneration markers. Among converters, higher baseline FW was associated with a faster annualized increase in amyloid PET SUVR.

CONCLUSIONS: Our findings indicate that baseline diffusion MRI markers of ISF dynamics are associated with subsequent Aβ-positivity conversion and Aβ accumulation in initially Aβ (-) CN individuals, suggesting that alterations in ISF dynamics may be detectable before overt Aβ deposition.

RevDate: 2026-11-19

Khan MV, Hussain MK, Rabbani G, et al (2026)

Revisiting the role of fluorescent dyes in the detection of amorphous and amyloid aggregates: The quest continues.

Biotechnology advances pii:S0734-9750(26)00308-3 [Epub ahead of print].

Protein aggregation is a hallmark of various neurodegenerative and systemic disorders, including Alzheimer's disease, Parkinson's disease, and type 2 diabetes. The ability to detect and characterize aggregates in both in vitro and in vivo systems is crucial for understanding disease mechanisms and developing diagnostic strategies. Fluorescent dyes have emerged as powerful tools for probing protein aggregates, offering insights into their structural variations and formation pathways. This review provides a comprehensive comparison of classical and emerging fluorescent dyes. It correlates their binding specificity and performance metrics, including quantum yield, fluorescence enhancement, and binding affinity, with molecular recognition mechanisms such as TICT restriction, π-π stacking, hydrophobic interactions, and electrostatic interactions. We categorize the dyes based on their blood-brain barrier (BBB) crossing ability, positron emission tomography (PET) imaging suitability, environmental sensitivity, nucleic acid binding affinity, luminescent conjugated oligothiophenes (LCOs), and nanoparticle-conjugation. We also consider their applicability to in vitro, in vivo and ex vivo settings, highlighting their use in detecting different aggregate species. We further assess dye suitability for amyloid versus amorphous aggregates and for different experimental contexts, considering critical parameters. By bridging structural features with functional outcomes, this review offers guidance for probe selection and highlights future directions for rational dye design to enhance sensitivity and selectivity in aggregate detection.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Frank A, Ismail Z, Wilson M, et al (2024)

Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 51(6):723-731.

Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 60%-70% of patients with dementia, and it is estimated that over one million Canadians will be living with dementia by 2030. Disease-modifying therapies (DMTs) targeting the underlying pathophysiology of AD are currently in development. Several models have demonstrated that the potential arrival of Alzheimer's DMTs will most likely overwhelm the already-constrained Canadian healthcare system. Canada does not have a strategy to address the extensive requirements of using DMTs, including providing an early diagnosis of AD, confirming DMT eligibility via amyloid biomarkers, and conducting ongoing treatment monitoring. Thus, a multidisciplinary group of experts involved in AD care in Canada gathered to review (1) the current barriers to diagnosis and management of AD; (2) how existing clinic models, including those used in multiple sclerosis (MS), could be applied to address key barriers in AD; and (3) how to design and implement optimal care pathways in the future. The actions outlined in this review will help clinicians and healthcare systems improve readiness to integrate the use of disease-modifying therapies in Alzheimer's disease, if such therapies are approved in Canada.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Wang YM, Wang M, Huang YL, et al (2026)

[Mechanisms of Shenghui Decoction in activating PPARα to promote microglial phagocytosis and degradation of Aβ].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 51(20):5858-5866.

This study aimed to elucidate the potential mechanisms by which Shenghui Decoction(SHD) promotes microglial cells to phagocytose and degrade surrounding deposited β-amyloid protein(Aβ) through the peroxisome proliferator-activated receptor α(PPARα)/transcription factor EB(TFEB) signaling pathway. Multiple approaches, including Western blot, real-time quantitative PCR(RT-qPCR), molecular docking, reporter gene assays, and immunofluorescence, were employed for verification. Mouse microglial cells(BV2 cells) were divided into the control group, model group, positive control(WY14643) group, and SHD low-, medium-, and high-dose groups(50, 100, and 200 μg·mL~(-1)), respectively. An Aβ-induced BV2 cell injury model was established, and different reagents were added according to group assignment. BV2 cell viability was assessed using the MTT assay. Fluorescently labeled Aβ_(1-42)(FAM-Aβ_(1-42))was used to evaluate Aβ phagocytosis and degradation in each group. Reporter gene assays were performed to determine the transcriptional activities of PPARα and TFEB. RT-qPCR was conducted to detect the expression of low-density lipoprotein receptor(LDLR), autophagy-related genes 5 and 7(Atg5 and Atg7), and lysosome-associated membrane protein 2(LAMP2). Western blot was used to determine the expression levels of PPARα, LDLR, TFEB nuclear translocation, microtubule-associated protein 1 light chain 3 Ⅰ and Ⅱ(LC3Ⅰ and LC3Ⅱ), P62, and LAMP2 proteins. Immunofluorescence was employed to further validate TFEB nuclear translocation. Molecular docking analysis was conducted to evaluate the binding between SHD active constituents and the ligand-binding domain of PPARα. The results showed that SHD had no significant effect on BV2 cell viability at concentrations of 50-300 μg·mL~(-1). SHD enhanced Aβ phagocytosis and degradation, upregulated LDLR expression, significantly increased the nuclear translocation and expression levels of PPARα and nuclear TFEB proteins, and enhanced the transcriptional activities of PPARα and TFEB. SHD significantly upregulated the expression of the autophagy-related genes Atg5 and Atg7 and the lysosome-related gene LAMP2, increased the protein expression levels of LC3Ⅱ/LC3Ⅰ and LAMP2, and significantly decreased P62 protein expression. Molecular docking results indicated that 50 active constituents in SHD could bind to the ligand-binding domain of PPARα and form stable hydrogen bonds, with binding energies <-5 kcal·mol~(-1). In summary, SHD improves the autophagic-lysosomal function in BV2 cells, thereby facilitating the phagocytosis and degradation of Aβ. This underlying mechanism is likely associated with the activation of the PPARα/TFEB signaling pathway.The findings of this study help elucidate the modern scientific connotation of SHD and may provide a rational therapeutic strategy for the clinical prevention and treatment of Alzheimer's disease.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Zhou Y, Che ZX, Chen LJ, et al (2026)

[Effects of Tongqiao Huoxue Decoction on cognitive dysfunction and expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 51(20):5930-5938.

To investigate the effects of Tongqiao Huoxue Decoction(TQHX) on cognitive dysfunction and the expression of insulin signaling pathway-related proteins in rats with Alzheimer's disease(AD), Sprague-Dawley(SD) rats were randomly divided into a sham-operated group, an AD group, a low-dose TQHX group, a medium-dose TQHX group, a high-dose TQHX group, and a positive control group. Following 28 days of treatment with TQHX or the positive control drug memantine, the homeostasis model assessment of insulin resistance(HOMA-IR) was determined. Cognitive function was evaluated using the Morris water maze. Hematoxylin-eosin(HE) staining and silver staining were performed to examine neuronal and synaptic morphology in the hippocampal CA1 region, and neuronal regeneration was assessed by immunofluorescence staining for doublecortin(DCX). The mitochondrial membrane potential(MMP) of brain tissue cells was measured using the JC-1 fluorescent probe, and adenosine triphosphate(ATP) levels were determined. The content of Aβ in brain tissue and the levels of malondialdehyde(MDA) and superoxide dismutase(SOD) were measured. Serum inflammatory cytokine levels were determined by ELISA. The expression of insulin signaling pathway-related proteins in brain tissue was detected by Western blot. The results showed that, compared with the sham-operated group, the AD group exhibited significantly increased HOMA-IR, escape latency, Aβ content, MDA levels, tumor necrosis factor-α(TNF-α), interleukin(IL)-1β and IL-8 levels, as well as increased ratios of phosphorylated glycogen synthase kinase-3β(p-GSK-3β)/glycogen synthase kinase-3β(GSK-3β) and phosphorylated nuclear factor-κB p65(p-NF-κB p65)/nuclear factor-κB p65(NF-κB p65), whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, insulin receptor(IR) protein expression, the ratio of phosphorylated insulin receptor substrate 1(p-IRS1)/insulin receptor substrate 1(IRS1), the ratio of phosphorylated phosphoinositide 3-kinase(p-PI3K)/phosphoinositide 3-kinase(PI3K), and the ratio of phosphorylated protein kinase B(p-AKT)/protein kinase B(AKT) were significantly decreased. Compared with the AD group, all TQHX treatment groups and the positive control group showed decreased HOMA-IR, escape latency, Aβ content, MDA levels, TNF-α, IL-1β, IL-8 levels, and the p-GSK-3β/GSK-3β and p-NF-κB p65/NF-κB p65 ratios, whereas the number of platform crossings, hippocampal DCX-positive expression, neuronal dendritic spine density, MMP, ATP, SOD levels, IR protein expression, and the p-IRS1/IRS1, p-PI3K/PI3K, and p-AKT/AKT ratios were all increased. Moreover, these effects showed a dose-dependent trend among the TQHX groups. Compared with the high-dose TQHX group, no significant changes were observed in any of the measured parameters in the positive control group. In conclusion, TQHX improves cognitive dysfunction and insulin resistance in AD rats and upregulates the expression of insulin signaling pathway-related proteins.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Menon P, VAN DEN Bos M, S Vucic (2026)

Utility of transcranial magnetic stimulation in the diagnosis of neurologic disorders.

Handbook of clinical neurology, 220:263-281.

Transcranial magnetic stimulation (TMS) techniques provide unique insights into human motor cortical physiology and have emerged as an important diagnostic investigation in a variety of neurologic disorders. Single-, paired-, and triple-pulse TMS techniques, incorporating the conventional amplitude-based and threshold tracking methodology, have established clinical and diagnostic utility in amyotrophic lateral sclerosis (ALS), dementias, movement and functional disorders, myelopathies, and neuroinflammatory diseases. Cortical hyperexcitability has emerged as an important diagnostic aid in ALS, and recent commercialization of the threshold-tracking software may facilitate translation into clinical practice. Single-pulse TMS measures have exhibited diagnostic utility in myelopathy even in the absence of radiologic changes. Short-latency afferent inhibition (SAI), reflecting central cholinergic transmission, is reduced in Alzheimer disease and mild cognitive impairment, serving as a surrogate diagnostic biomarker. Triple stimulation technique enhances the detection of upper motor neuron dysfunction and may aid diagnostic demyelinating neuropathies by establishing the presence of proximal conduction block in the cervical nerve root region. The present review discusses the physiologic processes underlying TMS measures and focuses on their diagnostic utility in neurologic diseases.

RevDate: 2026-11-17

Nayak S, MA Lodato (2026)

Developmental and age-acquired somatic mutations in neurodegenerative diseases.

Trends in genetics : TIG pii:S0168-9525(26)00263-5 [Epub ahead of print].

Classical genetic studies have assumed a uniform genome across the body, but humans are genetic mosaics harboring distinct somatic mutations acquired during development and aging. The role of somatic mosaicism in neurodegenerative disease remains poorly understood. In this article, we review somatic mosaicism in two contexts: developmental mosaics arising during embryogenesis and age-associated clonal expansions. Developmental mosaics are established contributors to neurodevelopmental disorders, with emerging evidence linking them to adult-onset neurodegeneration, including amyotrophic lateral sclerosis and Alzheimer's disease. Postnatal clonal expansions in microglia and hematopoietic cells may further promote systemic inflammation and disease progression. We synthesize these findings into a framework in which developmental and age-acquired mutations contribute to neuronal vulnerability, disease heterogeneity, and the pathogenesis of sporadic neurodegenerative disorders.

RevDate: 2026-11-17

Huang Y, Wei Y, Mao Y, et al (2026)

Topological visual perception and innate defense: Shared subcortical pathway for early diagnosis and neural plasticity intervention in brain disorders.

Neural regeneration research pii:01300535-990000000-01415 [Epub ahead of print].

The superior colliculus-pulvinar-amygdala subcortical pathway has long been recognized as a key pathway mediating innate defensive behaviors and rapid threat detection. Emerging evidence indicates that this pathway additionally supports unconscious topological visual perception, a primitive, evolutionarily conserved visual function that extracts global object structure independently of emotional valence. Notably, topological perception and threat detection are functionally distinct yet engage shared anatomical nodes within the superior colliculus-pulvinar-amygdala pathway, likely through partially segregated local subcircuits. As an emotion-neutral, robust, and unconscious marker, topological perception is hypothesized to be a potential functional probe for early subclinical dysfunction across brain disorders. Cumulative cross-sectional evidence suggests that functional impairments within the superior colliculus-pulvinar-amygdala pathway may emerge at early or subclinical stages across multiple neurodegenerative, mood-related, and neurodevelopmental disorders (e.g., Alzheimer's disease, Parkinson's disease, affective disorders, schizophrenia, and autism spectrum disorder), though longitudinal cohort data are still required to verify whether these alterations constitute genuine preclinical pathological events that precede overt clinical symptoms. Importantly, this pathway retains strong intrinsic neural plasticity and regenerative potential, supporting its suitability for early non-invasive intervention. This review summarizes the dual functions of the superior colliculus-pulvinar-amygdala pathway in fundamental topological visual perception and threat-detection-related defense, and outlines its specific structural and functional abnormalities across various brain disorders. We further systematically evaluate interventions including behavioral training, real-time neurofeedback, temporal interference stimulation, transcranial ultrasound, and pro-regenerative pharmacologic agents to restore circuit function and enhance neural plasticity. We propose that the superior colliculus-pulvinar-amygdala pathway represents a promising novel transdiagnostic target for early diagnosis and neural plasticity-based regenerative intervention in brain disorders, although validation in large-scale human longitudinal cohorts is still required.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Gong W (2026)

Computational identification of amyloid-mimicking microbial peptides with predicted MHC-II presentation relevance to Alzheimer's disease.

NPJ systems biology and applications, 12(1):.

Accumulating evidence suggests a link between gut microbiota, host immunity, and Alzheimer's disease (AD), while specific MHC-II alleles have been associated with disease susceptibility or protection. Here, we applied a computational framework to investigate whether microbial proteins contain amyloid-like motifs capable of interacting with Aβ42 and whether such peptides are differentially presented by distinct MHC-II alleles. We identified an aggregation-prone core within Aβ42 and screened AD-associated gut microbial proteomes to detect homologous peptide motifs. Predicted antigen presentation was evaluated using IEDB, and potential co-aggregation was assessed in silico. We identified microbial amyloid-mimicking peptides predicted to be presented by AD-associated MHC-II alleles, whereas fewer candidate peptides were identified for the protective alleles. Several peptides shared sequence similarity with Aβ42 aggregation motifs and demonstrated predicted structural compatibility for co-aggregation. These findings suggest a potential link between microbial peptide mimicry, antigen presentation, and amyloid biology. This study is computational and hypothesis-generating, providing a systems-level framework for understanding microbiota-immune interactions in AD.

RevDate: 2026-11-17

Mullard A (2026)

'Light and sound' therapy for Alzheimer's flops in long-anticipated trial.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Afshar FK, Nematollahi-Mahani SN, Haghpanah T, et al (2026)

Neuroprotective effects of the petroleum ether fraction of Teucrium polium in free and lipid nanoparticle formulations on cognitive deficits and oxidative stress in an ICV-STZ-induced Alzheimer's-like rat model.

Journal of molecular histology, 58(1):.

BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and neuronal loss. Current pharmacological treatments provide only partial symptomatic relief. This study investigated the neuroprotective effects of the petroleum ether fraction of Teucrium polium (T. polium), administered in both free and lipid nanoparticle formulations (T. polium-LNP), in a rat model of AD-like pathology induced by intracerebroventricular streptozotocin (ICV-STZ).

METHODS: Adult male Wistar rats were divided into five groups: Control, ICV-STZ, ICV-STZ + Memantine, ICV-STZ + T. polium, and ICV-STZ + T. polium-LNP. Cognitive function was assessed using the Morris water maze (MWM) and novel object recognition (NOR) tests. Serum oxidative stress markers-including malondialdehyde (MDA), total antioxidant capacity (TAC), and superoxide dismutase (SOD) activity-were measured. Hippocampal CA1 histopathology and hippocampal mRNA expression of Bax, Bcl-2, and p53 were also evaluated.

RESULTS: The ICV-STZ-induced AD-like model was associated with memory impairment, increased serum MDA levels, reduced TAC levels and SOD activity, and hippocampal CA1 neuronal damage, accompanied by increased Bax and p53 expression and decreased Bcl-2 expression. Treatment with T. polium and T. polium-LNP improved cognitive performance, particularly spatial memory in the MWM, and attenuated several pathological changes. Both treatments reduced serum MDA levels and decreased CA1 neuronal degeneration.

CONCLUSION: In this experimental AD-like rat model, both formulations of T. polium were associated with improvements in cognitive performance, serum oxidative status markers, and hippocampal tissue changes. Although T. polium-LNP showed numerically greater effects on several outcomes, direct comparisons between the free T. polium extract and T. polium-LNP were statistically significant only for CA1 neuronal damage. Further mechanistic and long-term studies are needed to clarify the potential relevance of these findings to AD-related neuroprotection.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Rentsch P, Konen LM, Zhu BH, et al (2026)

Late-onset Alzheimer's Disease Pathologies in a Novel hAβ/ApoE4 Mouse Line.

Molecular neurobiology, 63(1):.

Most Alzheimer's disease (AD) cases are late-onset and sporadic, yet existing mouse models predominantly reflect familial, autosomal-dominant forms. To address this gap, we present the first characterisation of hAβ/ApoE4 mice, which carry a humanised amyloid-beta (Aβ) sequence knocked into the endogenous amyloid precursor protein (APP) locus and a human apolipoprotein E4 (ApoE4) allele replacing murine ApoE, in the context of age-associated AD phenotypes. We aged hAβ/ApoE4 mice of both sexes to 12 months and assessed AD-relevant pathologies including cognition, spine loss, neurodegeneration, neuroinflammation and Aβ deposition. At 12 months, hAβ/ApoE4 mice exhibited spatial memory deficits in the Barnes maze as well as modestly reduced apical dendritic spine density without hippocampal neuronal loss. This model offers a platform for introducing environmental stressors and co-morbidities and establishes a reference point for the development of next-generation sporadic AD models.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Meeker KL, Wisch JK, Petersen ME, et al (2026)

Sociodemographic and comorbidity factors mediate ethno-racial differences in plasma Alzheimer's disease biomarkers.

Alzheimer's research & therapy, 18(1):.

BACKGROUND: Ethno-racial disparities in Alzheimer's disease (AD) risk are well-documented, yet mechanisms underlying these differences remain poorly understood. This study investigates plasma AD biomarkers reflective of amyloid, tau, neurodegeneration, and inflammation across Hispanic, non-Hispanic Black/ African American, and non-Hispanic White adults, and examines whether social determinants of health (SDOH) and comorbidities mediate observed disparities.

METHODS: Data from the community-based Health and Aging Brain Study - Health Disparities (HABS-HD) included 1,256 Hispanic, 723 Black, and 1,243 non-Hispanic White participants. Group differences in plasma biomarkers (phosphorylated tau-217 [p-tau217], amyloid-β 42/40 ratio [Aβ42/40], phosphorylated tau-181 [p-tau181], total tau, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) were assessed using ANCOVA adjusted for age, sex, APOE-ε4 status, and cognitive status. Multiple mediation models tested whether social determinants of health (income, education, area deprivation, chronic stress, social support) and comorbidity factors (BMI, creatinine, total cholesterol, HbA1c, systolic blood pressure) mediate group differences, with covariates and mediators considered simultaneously, resulting in 22 mediation models.

RESULTS: Significant differences were observed across all plasma biomarkers. Both Black and Hispanic adults showed lower p-tau217 and p-tau181 compared to non-Hispanic White adults (p's < 0.001). Hispanic adults exhibited lower Aβ42/40 compared to both groups (p's < 0.05) and lower GFAP compared to non-Hispanic White adults (p = 0.002), but higher total tau (p's < 0.01) compared to both groups. Hispanics had higher NfL than Black adults (p < 0.001) but did not differ from non-Hispanic Whites, while Black adults had lower NfL than non-Hispanic White adults (p < 0.001). Comorbidity factors, particularly creatinine (10 of 22 models), BMI (8 models), and HbA1c (7 models), consistently mediated biomarker differences. SDOH factors demonstrated mediation for Aβ42/40, p-tau181, and NfL, with area deprivation and education as key mediators.

CONCLUSIONS: SDOH and comorbidities were associated with plasma AD biomarker differences observed across ethno-racial groups, though their influence varies by biomarker type and comparison group. Renal function (creatinine), metabolic factors (BMI, HbA1c), and structural disadvantages (area deprivation, education) emerged as critical factors. However, many effects remain unexplained, suggesting additional biological, environmental, or unmeasured social factors contribute to disparities. These findings highlight the need for precision medicine approaches that integrate biological, systemic health, and social contexts when interpreting biomarkers and guiding dementia prevention.

RevDate: 2026-11-17
CmpDate: 2026-11-18

Tian S, Zhao G, Zhang Y, et al (2026)

Furin deficiency in excitatory neurons leads to cognitive dysfunction and glutamatergic synaptic impairment.

Alzheimer's research & therapy, 18(1):.

BACKGROUND: Furin, a pivotal member of the proprotein convertase family, exhibits markedly diminished expression in both Alzheimer's disease (AD) patients and animal models. However, the precise mechanisms by which furin regulates AD-associated cognitive impairment have yet to be fully elucidated.

METHODS: In the present study, we generated excitatory neuron-specific Furin conditional knockout (Furin cKO) mice to investigate the effects and underlying mechanisms of furin deficiency on cognitive decline. We further overexpressed furin in excitatory neurons of 5×FAD transgenic AD model mice to explore the neuroprotective capacity of furin.

RESULTS: Compared with control littermates, Furin cKO mice displayed significant impairments in spatial memory alongside elevated anxiety-like behaviors, hippocampal atrophy, and blunted hippocampal long-term potentiation (LTP). Mechanistic analyses further revealed that these neurobehavioral and electrophysiological deficits stemmed from marked reductions in dendritic arbor complexity, spine density, and glutamatergic receptor expression throughout the hippocampus and cerebral cortex of Furin cKO mice. Conversely, neuron-specific overexpression of furin in excitatory neurons of 5×FAD transgenic mice exerted promising rescue effects on the cognitive deficits of this AD model. This functional restoration was accompanied by recovered dendritic and synaptic abundance, alleviated Aβ plaque deposition, and reduced reactive glial activation.

CONCLUSIONS: These data demonstrate that furin expression in excitatory neurons is critical for maintaining intact synaptic plasticity and normal cognitive function. Moreover, our findings indicate that furin likely serves as a promising therapeutic candidate for alleviating pathological progression in AD and other associated neurodegenerative disorders.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Komorowska J, Ranglani S, McCann H, et al (2026)

Increases in a pivotal bioactive peptide in specific brain regions reflect the progression of pathology in Alzheimer's disease.

Alzheimer's research & therapy, 18(1):.

BACKGROUND: Abnormal activation of a developmental process driven by a bioactive peptide T14, is posited as a key mechanism in the degeneration of the primarily vulnerable nuclei during the prodromal phase of Alzheimer's Disease (AD).

METHODS: We use a range of anatomical, biochemical and genetic approaches to explore changes in T14 and its target, α7nAChR, in AD and in individuals with mood disorders, a frequent prelude to the disease.

RESULTS: Using paired samples from the same patients, levels of T14 and α7nAChR increased in the hippocampus across the AD continuum. In contrast, in early Braak stages, T14 levels in the midbrain reach a plateau and are primarily localised to glia. Moreover, in a cognitively healthy cohort, CSF derived ex vivo revealed a differential profile between T14 and tau levels in individuals with mood disorders, a well-known precursor to AD. These observations confirm a key role of T14 in the neuropathology of AD. Finally, we show a Braak-stage dependant and selective increase in an acetylcholinesterase isoform (AChE-R) already associated with AD pathology, where the profile corresponds closely to that of T14, thereby providing further clues regarding its provenance.

CONCLUSION: By highlighting region and cell-specific changes in the T14 profile as AD progresses, this study further validates a key role for T14 in the progression of neurodegeneration. Finally, the mood disorder-dependent changes based on T14 in CSF might reflect dysfunction in the primarily vulnerable isodendritic core and as such be viewed as a possible, albeit non-exclusive, prelude to AD. Collectively, these results underscore the importance of T14 in AD aetiology and could aid the development of precise and effective therapeutics to target its progression.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Yaddaden A, Bier N, Pelletier J, et al (2026)

When minimal assistance is not enough: A transitional approach for critical errors of older adults during instrumental activities of daily living: A mixed-methods study.

Australian occupational therapy journal, 73(6):.

INTRODUCTION: Older adults often experience neurocognitive challenges that threaten their independence. Instrumental activities of daily living (IADLs) are vital indicators of home safety, as even a single critical error, such as task failure, can affect the ability to live independently. A clearer understanding of which errors are critical and how verbal cognitive assistance from clinicians or caregivers can reduce such errors is needed.

OBJECTIVES: This study aims to (1) describe the critical errors committed by older adults from the continuum of cognitive functioning during multiple IADLs; (2) identify the types of verbal cognitive assistance provided to address these errors and facilitate independence and security; and (3) identify the transition points at which occupational therapists shift to more direct assistance.

METHODS: We analysed video-recorded IADL assessments of 40 older adults at home, 19 of whom had a formal diagnosis of Alzheimer's disease or mild cognitive impairment and 21 of whom had no official diagnosis (NOD). Standardised assessments based on ecological observations of four IADL tasks were used. Videos were transcribed to capture all errors and assistance provided. Deductive qualitative and descriptive statistical analyses (mean, proportion, etc.) were used to identify the main difficulties and assistance types.

None RESULTS: Twenty-eight participants, including 11 with NOD, made at least one critical error (e.g., turning the stove to high before cooking, crossing a road without looking); 19 made more than two, including four with NOD. Thirty-one participants received verbal assistance at least once, and 22 received assistance multiple times (six with NOD). Thirteen participants, including six with NOD, reached a transition point requiring maximal compensatory intervention.

CONCLUSION: Identifying and understanding critical errors highlights moments of vulnerability in daily life. Tailored verbal cognitive assistance helps manage these situations, enabling continued engagement, autonomy, and support for ageing in place even amid cognitive decline.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Min E, Harrison TM, Landau SM, et al (2026)

Apolipoprotein E genotype, PET and MRI biomarkers, and vascular risk: A multi-modal investigation of memory performance in US POINTER.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: The apolipoprotein E (APOE) ε4 allele is a key genetic risk factor for Alzheimer's disease (AD), but the etiology of impairment in non-carriers is less understood.

METHODS: We used regression and mediation models to test the cross-sectional relationships among APOE genotype, positron emission tomography amyloid and tau, vascular risk factors, and episodic memory within the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ancillary imaging dataset of non-demented older adults.

RESULTS: In our cohort (N = 880), APOE ε4 carriers showed higher global amyloid, higher meta-temporal tau, smaller hippocampal volume, poorer memory, and a stronger relationship between amyloid and tau standardized uptake value ratio (SUVR; ∆β = 0.22, p < 0.001). Tau predicted memory (p < 0.01) and partially mediated the APOE-memory association. In a stratified analysis, higher Framingham Heart Study risk score (FHS; p = 0.022) and not tau SUVR (p = 0.1) were associated with memory among APOE ε4 non-carriers, whereas tau SUVR (p = 0.048) but not FHS risk score (p = 0.55) was associated with memory amongst APOE ε4 carriers.

DISCUSSION: Drivers of cognitive performance appear to be specific to APOE ε4 carrier status, emphasizing the need to identify alternative, or contributing, disease mechanisms among non-carriers.

HIGHLIGHTS: The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is composed of older adults at elevated risk of cognitive decline and cardiovascular disease burden. Further multimodal neuroimaging data was collected through the POINTER Imaging ancillary study. At baseline evaluation, the apolipoprotein E (APOE) ε4 genotype was significantly associated with amyloid and tau pathology, hippocampal atrophy, and poor episodic memory performance. APOE ε4 genotype stratification analysis showed significant associations of Framingham cardiovascular risk score and smoking status with memory in non-carriers only. Etiological pathways of dementia may differ in contributive strength to cognitive deterioration within this at-risk cohort.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Thijssen EH, Eghzawi A, Gibellini F, et al (2026)

Capillary brain-derived p-tau217 for remote triaging of Alzheimer's disease pathology: Clinical performance in a CLIA/CAP-certified laboratory.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Expanding access to Alzheimer's disease (AD) blood biomarker testing through capillary collection beyond clinic-based venipuncture could enable earlier biological triage, specialist referral, and timelier initiation of disease-modifying therapies. Prior attempts to measure phosphorylated tau at amino acid 217 (p-tau217) in capillary blood have not achieved the diagnostic accuracy required for triaging.

METHODS: This was a cross-sectional diagnostic validation study (January 2025-April 2026) across six US sites. Adults aged ≥ 50 years with cognitive concerns were recruited, including a community-based sample (N = 180) and specialty memory/research clinic sample with available amyloid positron emission tomography (PET; N = 64; total N = 244). Same-day paired capillary (Tasso upper-arm device) and venous samples were shipped ambient overnight and processed at a Clinical Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP)-certified laboratory via proprietary capillary-to-assay workflow. Samples were measured using the BD-pTau217 singleplex assay on the NULISA platform.

RESULTS: Among 244 participants (mean age 64.3 [standard deviation 11.9] years; 153 female [62.7%]; 51 Black [20.9%]), capillary and venous brain-derived p-tau217 (BD-p-tau217) correlated (R = 0.93, ρ = 0.73; both P < 0.001), with concentration-dependent bias on Bland-Altman analysis. In the PET-confirmed cohort (N = 64), capillary BD-p-tau217 yielded area under the curve (AUC) 0.959 (95.7% sensitivity, 83.3% specificity; positive predictive value [PPV] 93.6%, negative predictive value [NPV] 88.2%), meeting Global CEO Initiative on Alzheimer's Disease (CEOi) low-specificity and Alzheimer's Association guideline triage thresholds. Across the full cohort at 26% amyloid prevalence, against a composite reference standard, AUC was 0.959 (90.5% sensitivity, 89.0% specificity; PPV 74.0%, NPV 96.4%), meeting CEOi high-specificity triage thresholds.

DISCUSSION: Capillary BD-p-tau217 met clinical performance standards for remote AD triage, to our knowledge the first capillary p-tau217 test to meet these standards, suggesting it may support triage of patients for further diagnostic evaluation, including specialist referral and confirmatory testing.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Zaheed AB, Oryshkewych N, Yu L, et al (2026)

Sleep-cognition associations change direction with proximity to dementia diagnosis.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Differentiating aspects of sleep health that are modifiable risk factors from prodromal symptoms or consequences of dementia can inform dementia prevention and/or clinical screening efforts, and temporal mapping of sleep-cognition associations can further inform mechanistic hypotheses regarding the role of sleep leading up to dementia diagnosis. We examined bidirectional associations between cognitive function and three modifiable sleep health features, and whether these associations vary by proximity to dementia diagnosis.

METHODS: 291 preclinical dementia participants (median initial age = 83 years, 73% female) and 281 matched cognitively unimpaired 'controls' from the Rush Memory and Aging Project completed up to 11 annual assessments of global cognition (composite of 19 neuropsychological measures) and actigraphy-derived measures of sleep amount, regularity, and timing. Linear mixed-effects models tested whether bidirectional sleep-cognition relationships differed by years-to-dementia diagnosis (preclinical dementia sample) or years-to-last follow-up (matched controls) after adjusting for sociodemographic and health covariates.

RESULTS: In the preclinical dementia sample, time-to-dementia modified the effects of sleep amount (both β = 0.02) and regularity (-0.04 < β < 0.02), but not timing, on next-year global cognition. Ten years before dementia diagnosis, longer and more irregular sleep predicted better next-year cognition; 1 year before diagnosis, these sleep patterns predicted worse next-year cognition. While sleep amount unidirectionally predicted subsequent cognition, sleep regularity-cognition associations were consistently bidirectional. These patterns were not observed in matched controls.

DISCUSSION: Changes in sleep-cognition associations over time may differentiate preclinical dementia from normal aging. Future research should investigate the driving mechanisms and modifiability of these sleep-cognition associations.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Chen J, Reheman P, Jin J, et al (2026)

Network architecture of sleep, biomarkers, and cognition: Rapid eye movement sleep latency as a cross-domain connector.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Sleep disturbances are linked to Alzheimer's disease (AD) and related dementias (ADRD) pathology and cognitive decline, but how sleep architecture, biomarkers, and cognition are organized within a conditional dependence framework remains unclear.

METHODS: We studied 98 adults spanning normal cognition (NC; n = 21), mild cognitive impairment (MCI; n = 34), and clinically diagnosed AD dementia (n = 43) using overnight polysomnography, plasma phosphorylated tau181 (p-tau181), neurofilament light chain (NfL), brain-derived neurotrophic factor (BDNF), amyloid-β positron emission tomography (PET), and multidomain cognitive testing. A regularized Gaussian graphical model was used to characterize conditional associations and identify cross-domain connectivity among sleep, biomarkers, and cognition.

RESULTS: The 17-variable network contained 26 edges, with significantly denser within-domain than cross-domain connectivity (40.5% vs 9.6%; p < 0.001). Direct sleep-cognition connections were sparse. Rapid eye movement (REM) sleep latency had the highest bridge strength (0.387), directly connecting the sleep domain with NfL, amyloid-β PET, and BDNF. Plasma p-tau181 was the only biomarker directly connected to global cognition. Exploratory mediation analyses were consistent with indirect associations involving p-tau181 in three of five cognitive domains.

DISCUSSION: Sleep architecture and cognition were conditionally linked primarily through biomarker nodes. REM sleep latency and plasma p-tau181 may represent key cross-domain connectors linking sleep architecture, neurodegeneration, and cognition across the AD continuum.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Chen HC, Gao FL, He C, et al (2026)

Pericyte PDGFR-β deficiency contributes to Aβ pathology through impaired glymphatic transport and altered AQP-4 localization.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Pericyte platelet-derived growth factor receptor-β (PDGFR-β) signaling maintains neurovascular integrity, but its role in glymphatic function is unknown. We investigated whether pericyte PDGFR-β deficiency is associated with glymphatic dysfunction and altered aquaporin-4 (AQP-4) localization in Alzheimer's disease (AD).

METHODS: Glymphatic trafficking was assessed by fluorescent cerebrospinal fluid (CSF) tracer injection. Meningeal lymphatic drainage was blocked by deep cervical lymph node (dcLN) ligation. Pericyte coverage, AQP-4 expression/localization, and basement membrane components were analyzed by immunofluorescence and western blot. Pericyte-conditioned medium was used to examine the effects of pericyte-derived factors on astrocytic AQP-4. The AQP-4 facilitator TGN-073 was administered to assess functional rescue. Blood-brain barrier integrity, microvascular density, and cerebral blood flow were also evaluated.

RESULTS: DcLN ligation impaired amyloid beta clearance and spatial memory. Both APP/PS1 and Pdgfr-β+/- mice exhibited pericyte loss and glymphatic dysfunction, with Pdgfr-β+/- mice additionally showing reduced perivascular AQP-4 expression, accompanied by decreased laminin-α2/β1. In vitro, pericyte-derived factors promoted AQP-4 expression. TGN-073 partially improved small-molecule CSF tracer distribution in Pdgfr-β+/- mice. Pdgfr-β+/-/APP/PS1 mice displayed exacerbated AD-like pathology.

DISCUSSION: PDGFR-β deficiency compromises basement membrane integrity and AQP-4 localization, impairing glymphatic transport and accelerating AD pathogenesis. The PDGFR-β pathway may represent a novel therapeutic target for enhancing waste clearance.

RevDate: 2026-11-18

Lim XYH, Tan WJ, Jiang W, et al (2026)

Arts-based involvement is associated with positive perceptions of dementia in Singapore: an item-level perspective.

Arts & health [Epub ahead of print].

BACKGROUND: Arts-based programmes have shown promise in enhancing perceptions towards dementia, but research on such initiatives is scarce in the Asia-Pacific region. We investigated how involvement in an arts-based programme designed for persons living with dementia in Singapore is associated with attitudes towards dementia.

METHODS: A cross-sectional survey design was employed with 75 community members aged 19 to 68 (M = 42.07, SD = 13.77) with three levels of involvement in the programme: low involvement, high involvement, and newly inducted community members. Participants rated items on the Approaches to Dementia Questionnaire and Dementia Attitudes Scale. Quantitative data were analysed in R software.

RESULTS: Compared to community members with low involvement and those who are newly inducted, participants with high involvement reported significantly higher hope (ηp[2] = .18) and personhood (ηp[2] = .17). Arts-based involvement was positively associated with hope (rs = .40, p < .001), personhood (rs = .32, p = .005), and knowledge (rs = .28, p = .014), but not comfort (rs = .07, p = .528). Item-level analyses revealed that high involvement in the programme was associated with greater endorsement of flexible routine (ηp[2] = 0.09), hope (ηp[2] = .14), independent decision-making (ηp[2] = .12), and the importance of conversations (ηp[2] = .52).

CONCLUSIONS: Involvement in arts-based programmes is associated with viewing persons living with dementia through a more empowering lens - recognising their capacity for independent decision-making, valuing meaningful conversations, endorsing that dementia care need not be overly regimented, and holding greater hope for their dignity.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Chen L, Zhang J, Wang Z, et al (2026)

Aβ42 induces selective degeneration in hippocampal cells of aged monkeys.

Zoological research, 47(6):2151-2167.

The hippocampus is one of the earliest and most severely affected brain regions in Alzheimer's disease (AD) and is critical for memory formation. However, the precise mechanisms through which AD disrupts hippocampal neurons remain poorly understood. To investigate the effects of Aβ42 in a model closer to humans, we performed stereotaxic injections of an adeno-associated virus serotype 9 (AAV9) vector encoding human Aβ42 into the hippocampus of young (7-year-old) and aged (>20-year-old) cynomolgus monkeys. We found that AAV9-mediated Aβ42 expression induced more severe neuropathology, reduced daytime activity, and increased sleep disturbances in aged monkeys compared to young controls. Single-nucleus RNA sequencing (snRNA-seq) revealed an age-dependent reduction in disease-associated microglia subtype II (DAM II) in the aged hippocampus. Furthermore, we identified a specific subtype of hippocampal pyramidal neurons (PCs) (TRPS1 [+] RELN [+]) that is selectively vulnerable to Aβ42 toxicity in aged monkeys. Our findings indicate that Aβ42 toxicity is exacerbated in the aged primate hippocampus due to a combination of microglial decline and the selective vulnerability of a distinct neuronal subtype (TRPS1 [+] RELN [+] PCs). This identified subtype represents a new potential therapeutic target for treating hippocampal dysfunction in AD.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Wang H, Wang X, Gong H, et al (2026)

Aβ Aggregate-Gated Ratiometric Probe Reveals Peri-Plaque Acidification Arising from Lysosomal Dysfunction in Alzheimer's Disease.

ACS chemical neuroscience, 17(22):3701-3714.

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques surrounded by plaque-associated dystrophic neurites (PADNs), where dysfunctional autolysosomal vesicles accumulate abundantly. However, whether Aβ-induced autolysosomal dysfunction contributes to remodeling of the plaque microenvironment remains unclear. Herein, we developed DQ, an Aβ aggregate-gated ratiometric fluorescent probe in which recognition of fibrillar Aβ activates pH-responsive fluorescence. This target-triggered sensing strategy restricts pH reporting to the vicinity of Aβ aggregates, enabling selective visualization of local plaque-associated microenvironments with minimal background interference. DQ exhibited high selectivity toward fibrillar Aβ and enabled imaging of local pH changes in both cellular models and transgenic AD mice. Using DQ, we revealed progressive acidification surrounding plaques during AD progression and demonstrated an age-dependent increase in peri-plaque acidification. Furthermore, imaging analyses showed that local acidification was closely associated with lysosomal dysfunction within PADNs. Mechanistic studies further demonstrated that autolysosomal impairment within PADNs causes lysosomal proton leakage and microenvironmental acidification. Repair of lysosomal dysfunction alleviated multiple AD-associated pathological features, including plaque burden, neuroinflammation, synaptic loss, and cognitive impairment. Collectively, this work establishes a target-gated ratiometric sensing strategy for spatially resolved interrogation of plaque-associated microenvironments and identifies PADN-associated lysosomal proton dysregulation as an important pathological event in AD progression.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Sindhu N, Jain S, Sharma S, et al (2026)

A Mito-CoQ10-TPP Nanocarrier Hybrid Enhances the Therapeutic Efficacy of Mitochondrial Transplantation in Alzheimer's Disease.

ACS chemical neuroscience, 17(22):3653-3667.

Mitochondrial dysfunction is an early pathological aspect of Alzheimer's disease (AD) that promotes oxidative stress, leading to amyloid β-plaque formation and neurofibrillary tangles. Thus, targeted mitochondrial therapy and mitochondrial transplantation have emerged as promising therapeutic strategies. However, excessive oxidative stress and neuroinflammation in the microenvironments of the AD brain limit the functional and stable integration of transplanted mitochondria. In this study, we have engineered a Mito-CoQ10-TPP hybrid nanocarrier by conjugating triphenylphosphonium (TPP), a lipophilic cation, with Coenzyme Q10 (CoQ10) and localized it to mitochondria isolated from healthy cortical brain cells. This nanocarrier hybrid was administered via a single intravenous (IV) dose to streptozotocin (STZ)-induced AD in mice. A comprehensive evaluation of mitochondrial function, amyloid burden, neuroinflammation, apoptosis, biogenesis, and behavior revealed that CoQ10-TPP conjugation significantly improved the mitochondrial transplantation efficacy in the amelioration of AD. Thus, conjugating the antioxidant CoQ10 with mitochondrial transplantation significantly improved the overall therapeutic efficacy, indicating the use of the Mito-CoQ10-TPP hybrid nanocarrier as a promising therapeutic strategy.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Shi X, Chen G, Lu F, et al (2026)

Functional impairment statistically mediates the association between hyperarousal neuropsychiatric symptoms and cognitive decline: a prospective cohort study.

Frontiers in aging neuroscience, 18:1968518.

INTRODUCTION: Neuropsychiatric symptoms (NPS) are prevalent in older adults and are associated with cognitive decline. This study investigated the association between hyperarousal NPS (HNPS) and cognitive progression, focusing on the mediating role of functional impairment and its link to Alzheimer's disease (AD) pathology.

METHODS: Using data from 1,657 non-demented participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), we evaluated the Hyperarousal Neuropsychiatric Inventory Questionnaire (HNPI-Q, comprising agitation, anxiety, and irritability), the Functional Activities Questionnaire (FAQ), APOE ε4 status, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores, regional brain volumes, and amyloid-β (Aβ) positron emission tomography (PET) Centiloid values. Analyses included Cox and linear regression, mediation analysis, and nomogram development.

RESULTS: HNPS predicted 5-year cognitive decline (HR = 1.14, p = 2.7 × 10[-4]), an association attenuated after adjusting for FAQ. HNPI-Q scores were longitudinally associated with functional and cognitive decline. Mediation analyses indicated that functional impairment statistically mediated the association between HNPS and cognition. Notably, the rate of functional decline was strongly correlated with the rate of Aβ accumulation, a coupling that was also evident in participants who progressed to cognitive deterioration. Predictive models based on HNPI-Q and FAQ showed excellent discrimination (AUC: 0.838 and 0.845) and calibration.

CONCLUSION: HNPS was associated with cognitive decline, an association that was statistically mediated by functional impairment, which itself co-varies with Aβ pathology. The HNPI-Q stratified the 5-year risk of cognitive deterioration in this cohort, and whether intervening on these symptoms or on functional decline alters the clinical course remains to be further investigated.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Almetwally EM, Diab LS, Ahmed MA, et al (2026)

Artificial intelligence applications in fMRI-based disease diagnosis: A systematic review.

Digital health, 12:20552076261491584.

OBJECTIVE: The purpose of this study is to critically assess and thoroughly explore the use of artificial intelligence (AI) methods in functional magnetic resonance imaging (fMRI) for the diagnosis of neuropsychiatric and neurological conditions. Methodological variability, dataset features, validation techniques, repeatability transparency, and the clinical preparedness of AI-based diagnostic models are the main topics of the review.

METHODS: A thorough search for research published between 2010 and 2025 was conducted using PubMed, Scopus, Web of Science, and IEEE Xplore. The review was conducted in accordance with PRISMA 2020. The PICOS framework was used to define the eligibility requirements. Studies were included if they published quantitative performance metrics and used resting-state or task-based fMRI data in conjunction with machine learning or deep learning models for disease classification. A modified QUADAS-2 framework appropriate for AI-based diagnostic research was used to evaluate the methodological quality and bias risk. Because study designs, datasets, preprocessing pipelines, and evaluation metrics varied, the data were synthesized qualitatively.

RESULTS: After the PRISMA 2020 screening procedure, 80 studies in all satisfied the inclusion requirements. The majority of research concentrated on autistic spectrum disorder, Parkinson's disease, Alzheimer's disease, and major depressive disorder. While machine learning methods (especially support vector machines) and deep learning architectures like convolutional neural networks and graph neural networks were the most commonly used artificial intelligence techniques, resting-state fMRI was the most commonly used imaging modality. In general, reported categorization accuracy fell between 85% and 96%. Nonetheless, significant methodological variation was noted in model topologies, validation techniques, feature extraction techniques, and preprocessing pipelines. Concerns about the generalizability of the model and possible overfitting were highlighted by the frequent dependence on very small cohorts and the sparse use of external validation. Additionally, quality assessment revealed moderate to high risks of bias in several studies, especially in relation to validation and patient selection processes.

CONCLUSION: The use of AI to analyze fMRI data shows great promise for enhancing the diagnostic categorization of neurological and neuropsychiatric disorders. However, clinical translation is restricted by small sample sizes, inconsistent methods, and a lack of external validation. To improve repeatability and facilitate the incorporation of AI-driven fMRI analysis into clinical practice, standardized preprocessing procedures, bigger multi-site datasets, open reporting procedures, and stringent external validation are necessary.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Fang Z, Yue J, Lu Q, et al (2026)

Ganoderic Acid A Ameliorates Recognition Memory Deficits and Anxiety- and Depression-Like Behaviors in APP/PS1 Mice: Association With Histone Lactylation and Ferroptosis.

Food science & nutrition, 14(11):e72603.

Alzheimer's disease (AD) is a degenerative disorder of the central nervous system, characterized by core symptoms of memory and cognitive dysfunction. However, neuropsychiatric abnormalities such as anxiety and depression are commonly observed during the progression of AD. Aberrant histone lactylation is a key epigenetic mechanism that promotes AD progression. Ganoderic acid A (GAA), one of the major bioactive components in Ganoderma lucidum, has been shown to ameliorate AD; however, whether GAA ameliorates anxiety- and depression-like behaviors in AD, and whether it exerts neuroprotective effects through regulation of the histone lactylation-ferroptosis axis, remain unexplored. In this study, using APP/PS1 mice as a model, recognition memory as well as anxiety- and depression-like behaviors were evaluated. Furthermore, an AD cell model was established by treating HT22 cells with Aβ25-35 to investigate the mechanism of GAA in vitro. The results showed that GAA improved recognition memory, anxiety-, and depression-like behaviors in APP/PS1 mice and suppressed histone lactylation in the hippocampus. In AD cells, GAA treatment was accompanied by decreased LDH levels, reduced lactate contents, p300 downregulation, HDAC1 upregulation and reduced histone lactylation. Ferroptosis-related assays showed that GAA treatment downregulated TFR1, upregulated FTH1, decreased Fe[2+] levels, downregulated ACSL4, upregulated NRF2, SLC7A11, and GPX4, and decreased ROS and MDA levels, while increasing SOD and GSH levels and total antioxidant capacity. Collectively, these findings indicate that GAA effectively ameliorates recognition memory deficits and anxiety- and depression-like behaviors in APP/PS1 mice, possibly via the histone lactylation-ferroptosis axis, thereby exerting anti-AD effects. Our study suggests that GAA could be exploited as a novel functional food ingredient for the treatment or prevention of AD.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Thiyagarajan R, Muniyandi V, Murugesan A, et al (2026)

GPR37 and GPR37L1-mediated neuroprotection: mechanisms and drug repurposing strategies for reducing neurological disorders.

Frontiers in aging neuroscience, 18:1947212.

Neurological disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, ischemic stroke, and neuropathic pain are major causes of long-term disability worldwide. The orphan G protein-coupled receptors GPR37 and GPR37L1 have gained considerable research attention as novel therapeutic targets. These receptors play critical roles in neuroprotection, neuroinflammation and tissue repair. GPR37 is primarily expressed in dopaminergic neurons and oligodendrocytes, whereas GPR37L1 is mainly expressed in astrocytes. These receptors modulate various cellular processes through Gi/o-coupled signaling, ERK/MAPK, and PI3K-Akt pathways. Both GPR37 and GPR37L1 affect neuronal survival, remyelination, oxidative stress, apoptosis, glial activation, and phagocytic clearance. Activation of GPR37 and GPR37L1 by their ligands, including prosaposin-derived peptides, neuroprotectin D1, and osteocalcin, regulates protective signaling and promotes functional recovery in the injured central nervous system. This review highlights recent progress in the cellular mechanisms regulating neuroprotection mediated by GPR37 and GPR37L1. This includes GPR37/GPR37L1 molecular characteristics and ligand signaling, mechanisms of proteostasis, ER stress, anti-apoptotic and survival signaling, modulation of oxidative stress, regulation of neuroinflammation, glial-mediated repair and remyelination, and synaptic and dopaminergic regulation. In addition, repurposed drugs targeting these receptors are also reviewed, along with a discussion on the clinical implications of GPR37/GPR37L1 in reducing neurological disorders. Despite these advances, a unified mechanistic framework linking receptor biology with therapeutic development remains lacking. This review proposes a conceptual framework that integrates receptor signaling, disease mechanisms, and drug repurposing strategies, while highlighting testable hypotheses on convergent neuroprotective pathways that warrant experimental validation. This systematic review was conducted in accordance with the PRISMA 2020 guidelines. By providing a translational perspective, this framework may facilitate biomarker discovery, prioritize therapeutic candidates, and accelerate the clinical development of GPR37/GPR37L1-targeted interventions for neurological disorders.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Remes TM, Ritari N, Arikoski PM, et al (2026)

Apolipoprotein ε4-allele as predictor of outcome in radiotherapy-treated childhood brain tumor survivors.

Neuro-oncology practice, 13(6):1089-1099.

BACKGROUND: Apolipoprotein E (APOE) is a polymorphic gene with three main alleles; the ε4-allele is a risk factor for distinct diseases, particularly for Alzheimer's disease. Radiotherapy-treated childhood brain tumor (BT) survivors face an increased risk of developing late-effects, especially cognitive impairment. Despite the similar treatment modality, the outcome varies considerably. Thus, we investigated the influence of ε4-allele on outcome in these survivors.

METHODS: A Finnish national cohort of radiotherapy-treated childhood BT survivors was investigated in a cross-sectional setting (median follow-up of 20 years). Survivors participated in the follow-up visit including neuropsychological and physical examinations, brain magnetic resonance imaging, and laboratory tests. BT and treatment-related information were collected from the patient files. APOE polymorphism was examined, and the results were compared to a previous study on the Finnish population. We also compared the late-effects between ε4-carriers and non-carriers.

RESULTS: Among 58 survivors [median age of 27 (range, 16-43) years], the observed frequencies of APOE genotypes were 78% (N = 45) for ε3ε3, 14% (N = 8) for ε3ε4, 7% (N = 4) for ε2ε3, and 2% (N = 1) for ε2ε4. The presence of ε4-allele was associated with poorer semantic, immediate, and delayed auditory memory. Since all ε4-carriers had ventriculoperitoneal shunt, we compared their results to those of non-carriers with ventriculoperitoneal shunt, which revealed that ε4-carriers had worse immediate and delayed auditory memory. E4-carriers exhibit higher total cholesterol and triglyceride levels than non-carriers.

CONCLUSIONS: APOE ε4-allele may impact the cognitive outcome and cholesterol levels in the radiotherapy-treated childhood BT survivors. E4-carrier survivors may especially benefit from healthy life-style interventions.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Liu J, Shan X, Li S, et al (2026)

Targeting the cGAS-STING axis in Alzheimer's disease: neuroinflammation-centric therapeutic strategies and perspectives.

Frontiers in pharmacology, 17:1983598.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder traditionally characterized by amyloid-β (Aβ) plaques and tau neurofibrillary tangles. However, the limited clinical efficacy of Aβ/tau-targeted therapies has redefined neuroinflammation as an active driver of AD pathogenesis. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis acts as a central hub connecting aberrant cytosolic nucleic acid sensing particularly mitochondrial DNA leakage induced by Aβ and tau pathologies to chronic innate immune activation. This review comprehensively elucidates the pathogenic mechanisms of the cGAS-STING axis in AD, detailing its cell-type-specific activation in microglia, astrocytes, and neurons, and its downstream propagation via type I interferons, NF-κB, and NLRP3 inflammasome signaling, which collectively drive synaptic damage and neuronal loss. We critically evaluate emerging therapeutic strategies, including covalent/non-covalent small-molecule inhibitors (e.g., RU.521, H-151, PF-06928215, SN-011), PROTAC degraders, RNA-based therapies, and immunomodulatory natural products/traditional Chinese medicines (e.g., icariin, tetrahydroxy stilbene glucoside, compound danshen dripping pills). Furthermore, we explore clinical translation prospects, emphasizing cerebrospinal fluid cGAMP and exosomal phosphorylated STING as minimally invasive biomarkers, while addressing key hurdles in blood-brain barrier penetration, and off-target risks. Finally, we highlight future directions involving organoid-microfluidic chip models and precision medicine frameworks to facilitate personalized cGAS-STING-targeted immunotherapy for AD.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Haider F, De La Fuente Garcia S, S Luz (2026)

SoniNet: an AI framework for enhancing voice features in speech-based health monitoring.

Frontiers in aging neuroscience, 18:1977352.

Deep learning based speech embeddings learned from large-scale speech corpora have achieved strong performance across a range of speech analysis tasks. However, handcrafted acoustic features, such as prosodic, spectral, and voice-quality descriptors, remain widely used in clinical speech analysis because of their established role in characterizing vocal behavior. Despite this, these features often struggle to generalize across variations in speech dynamics, recording duration, and recording conditions. This paper introduces SoniNet, a framework that enhances the discriminative power of handcrafted acoustic features by learning data-driven temporal representations from large-scale speech data. SoniNet captures the temporal evolution of acoustic descriptors across speech recordings of variable length while maintaining compatibility with established acoustic feature sets used in clinical speech analysis. We evaluate SoniNet on benchmark speech data sets and demonstrate consistent improvements in classification performance across clinical speech assessment tasks, outperforming conventional acoustic modeling approaches in 22 out of 24 feature-task combinations. These findings highlight the potential of SoniNet as a robust framework for speech-based health monitoring, affect recognition, and computational behavioral analysis.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Cuypers M, Celik A, Dimmendaal M, et al (2026)

Dementia in individuals with intellectual disabilities: An exploratory study of prevalence and mortality risk using Dutch routine care and population data.

Alzheimer's & dementia (Amsterdam, Netherlands), 18(4):e70542.

INTRODUCTION: Improvements in care for individuals with intellectual disabilities (ID) have increased life expectancy, but have also brought an increase in age-related conditions such as dementia. While Alzheimer's Dementia in Down syndrome is well-documented, data on overall dementia prevalence and related mortality across the broader ID population are limited.

METHODS: Exploratory analyzes were performed, using dementia data from a large regional Dutch primary care database and the national Dutch mortality registry. Descriptive statistics, odds ratios, and hazard ratios were calculated.

RESULTS: People with ID showed higher dementia prevalence at younger ages compared to those without ID and a higher risk of dementia-related mortality.

DISCUSSION: These findings suggest individuals with ID are diagnosed with dementia at younger ages than in the general population. There is a need for greater awareness of dementia in individuals with ID among health care providers, and increased knowledge on the distinct clinical characteristics in this population.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Qi C, Gu Y, Lei J, et al (2026)

Disulfidptosis in neurological disorders: from disulfide stress to actin cytoskeletal collapse.

Frontiers in aging neuroscience, 18:2003656.

The mechanisms driving irreversible neural cell loss in neurodegenerative diseases remain elusive. The collapse of cellular redox balance has unveiled a complex network of emerging metabolic cell death modalities that extend far beyond classical apoptosis. Disulfidptosis, a newly identified form of regulated cell death driven by disulfide stress and uniquely marked by actin cytoskeletal collapse, adds a critical dimension to this network. This review establishes an integrative framework-from sulfur metabolic imbalance to cytoskeletal collapse-for understanding this lethal pathway specifically within the nervous system. we focus on three features that are distinctive to neural tissue: the neuron-glia metabolic coupling that dictates which cell type is most vulnerable; the contrast between chronic disulfide stress dynamics in neurodegeneration and acute stress dynamics in ischemic stroke; and the blood-brain barrier (BBB) and cellular heterogeneity constraints that shape translational strategies. We first establish the cystine/cysteine cycle as the central hub of sulfur metabolism, revealing how it transforms from an antioxidant defense into a lethal driver of disulfide stress upon crossing a critical threshold. We then systematically dissect the molecular machinery of disulfidptosis, centered on NADPH depletion, the SLC7A11 bidirectional paradox, and aberrant cytoskeletal crosslinking. By systematically comparing disulfidptosis with ferroptosis and cuproptosis, we identify the SLC7A11-cystine-NADPH axis as a shared regulatory node. We further discuss how this mechanism may converge to contribute to neural cell injury across chronic neurodegenerative and acute neurological conditions, including Alzheimer's disease and Parkinson's disease, and may also extend to acute neurological conditions such as ischemic stroke. Finally, we propose a dual neuroprotective strategy targeting disulfidptosis and highlight its biomarker potential. Collectively, this review offers a new paradigm for understanding metabolic cell death in neurodegenerative diseases and lays a theoretical foundation for neuroprotective strategies targeting disulfide homeostasis.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Deng Y, B Hu (2026)

Ketogenic diet and ketone body metabolism in Alzheimer's disease: mechanisms, clinical evidence, and emerging perspectives.

Frontiers in nutrition, 13:1971568.

Alzheimer's disease (AD), the most common neurodegenerative disorder, is associated with progressive cognitive impairment, β-amyloid (Aβ) aggregation, and tau hyperphosphorylation, while currently available treatments provide only partial symptomatic relief or modestly slow disease progression. Cerebral glucose hypometabolism and neuronal energy deficiency can occur early in AD, making metabolic dysfunction a potential therapeutic target. The ketogenic diet (KD) restricts carbohydrate intake to stimulate hepatic ketogenesis and increase the availability of ketone bodies; its principal circulating metabolite, β-hydroxybutyrate (BHB), may influence AD-related processes through metabolic, epigenetic, and immunomodulatory pathways. This review summarizes proposed mechanisms and clinical evidence for ketogenic dietary interventions and exogenous ketone strategies in AD and mild cognitive impairment (MCI). BHB may provide an alternative oxidative substrate, influence mitochondrial and autophagy-related signaling, serve as a substrate for β-hydroxybutyrylation (Kbhb), inhibit selected histone deacetylases (HDACs), and modulate inflammatory pathways involving GPR109A and the NLRP3 inflammasome. These mechanisms are supported mainly by preclinical studies and have not been jointly validated in clinical trials. Human studies remain limited by small samples, heterogeneous interventions, short follow-up, and variable blinding and adherence. We therefore discuss safety, methodological limitations, and priorities for biomarker-informed clinical studies, while emphasizing that the clinical relevance of the proposed mechanisms remains to be established.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Tadesse S, Gebremariam AG, Jemal M, et al (2026)

Magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.

The journal of medicine access, 10:27550834261495456.

BACKGROUND: Neurological disorders are diseases or conditions that affect the brain, spinal cord, and nerves. Without understanding the magnitude and burden, it will be difficult to design evidence-based interventions. Therefore, this study will fill the information gap by analyzing the magnitude and burden of neurological disorders in Ethiopia, from 1990 to 2023.

METHODS: A retrospective, systematic analysis of secondary data was conducted. Estimates of age-standardized incidence, prevalence, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) were extracted. Percentage change was also used to assess trends in all metrics between 1990 and 2023. Each metric was estimated to be per 100,000 populations with a 95% uncertainty interval. The analysis included Level 2 and specific Level 3 cause categories, adhering to the GATHER guidelines for transparency.

RESULTS: In 2023, the overall age-standardized incidence rate of neurological disorders in Ethiopia was 7,588 per 100,000 population (95% UI: 6,659, 8,490) and the prevalence rate was 25,346 per 100,000 population (95%UI: 23,005, 27,886). While overall rates showed a slight, statistically significant decline, Parkinson's disease showed a significant increase in incidence of 14% (95% UI: 7%, 21%) and prevalence of 35% (95% UI: 25%, 45%). Headache disorders (tension-type headache and migraine) were the main drivers of YLDs, whereas idiopathic epilepsy and Alzheimer's disease were the leading contributors to YLLs and DALYs. The burden increases sharply after age 55. Notably, Parkinson's, motor neuron, and other neurological disorders exhibited significant increments across all primary burden metrics (DALYs, YLLs, and YLDs). Gender disparities were observed, with females bearing a higher burden of Alzheimer's and migraine, while males were more affected by Parkinson's disease.

CONCLUSION: The observed trends reflect a demographic transition toward an aging population. The slight decline in magnitude and insignificant change in burden likely reflect underdiagnosis and limited healthcare access rather than true epidemiological stability. These findings underscore the urgent need for targeted public health programs, including integrating neurological care into primary healthcare, developing age-specific and gender-responsive care strategies, and improving surveillance systems to monitor the rising burden in Ethiopia.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Wang D, Liu L, Sun T, et al (2026)

Pseudolaric Acid A and Pseudolaric Acid B Exert Dual Neuroprotection: Inhibiting Aβ-Induced PC12 Apoptosis and Neuroinflammation with Therapeutic Potential in Alzheimer's Disease Mice.

ACS pharmacology & translational science, 9(11):3264-3276.

OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disorder with no effective prevention strategy. This study explored the neuroprotective effects of pseudolaric acid A (PAA) and pseudolaric acid B (PAB) against Aβ25-35-induced PC12 cell apoptosis and their anti-inflammatory roles in macrophages/microglia. We also assessed PAB's therapeutic potential in an AD mouse model.

METHOD: To dissect the potential antiapoptotic and anti-inflammatory mechanisms of PAA and PAB, we established distinct in vitro models, including the Aβ25-35-induced PC12 apoptosis model and LPS-stimulated BV2 microglia/RAW264.7 macrophage inflammatory models. The effects of PAA and PAB on cell viability, apoptosis, inflammation, migration, NO release, ROS levels, miRNA-155 expression, and related protein expression were investigated in vitro. Subsequently, the AlCl3-induced AD mouse model was established, and the effects of PAB on spatial learning/memory abilities and hippocampal neurons were evaluated by the Morris water maze and HE staining.

RESULT: Our in vitro results showed that PAA and PAB could inhibit the apoptosis of PC12 cells induced by Aβ25-35 by regulating the expression of IRS-1, p-Akt, and p-GSK-3β. In parallel, PAA and PAB could alleviate the inflammatory response of macrophages and microglia induced by LPS by regulating the expression of P-Iκ-Bα/Iκ-Bα, TNF-α, and TGF-β1. Furthermore, behavioral tests showed that PAB had a certain therapeutic effect on AD model mice, as evidenced by improved spatial learning and memory.

CONCLUSION: Our in vitro findings indicate that PAA and PAB exert neuroprotective effects via two distinct mechanisms: inhibiting apoptosis through PI3K/Akt signaling and attenuating neuroinflammation through NF-κB/miR-155 modulation. In vivo, PAB improved cognitive function in AD model mice. Although further validation is required to confirm these mechanisms in vivo, these results support the therapeutic potential of PAA and PAB for AD.

▼ ▼ LOAD NEXT 100 CITATIONS

RJR Experience and Expertise

Researcher

Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.

Educator

Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.

Administrator

Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.

Technologist

Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.

Publisher

While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.

Speaker

Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.

Facilitator

Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.

Designer

Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.

963 Red Tail Lane
Bellingham, WA 98226

206-300-3443

E-mail: RJR8222@gmail.com

Collection of publications by R J Robbins

Reprints and preprints of publications, slide presentations, instructional materials, and data compilations written or prepared by Robert Robbins. Most papers deal with computational biology, genome informatics, using information technology to support biomedical research, and related matters.

Research Gate page for R J Robbins

ResearchGate is a social networking site for scientists and researchers to share papers, ask and answer questions, and find collaborators. According to a study by Nature and an article in Times Higher Education , it is the largest academic social network in terms of active users.

Curriculum Vitae for R J Robbins

short personal version

Curriculum Vitae for R J Robbins

long standard version

RJR Picks from Around the Web (updated 11 MAY 2018 )